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While liver transplantation is the only accepted therapy for liver failure, bound solute dialysis 
(BSD) may provide an alternative. Current BSD methods, MARS and SPAD, are unfortunately 
poorly characterized.  The studies presented here address basic questions involved in making 
BSD effective.  First, Biacore surface plasmon resonance (SPR) was used to measure binding 
and reaction rate constants of albumin-solute pairs relevant to designing and testing BSD 
systems.  Much is known about albumin equilibrium binding properties, but little is known 
regarding albumin-solute binding kinetics.  Additionally, testing and clinical application of BSD 
systems are often done at different temperatures (i.e. room temperature (22°C) and body 
temperature (37°C)), and changes in reaction rates and binding constants with temperature need 
to be considered.  Human and bovine serum albumin were immobilized on Biacore sensor chip 
surfaces, and reacting solutes (bilirubin, FK506, cyclosporine A, cholate, deoxycholate, and 
glycocholate) flowed across the surfaces.  The SPR response was tracked during the association 
and dissociation of the albumin-solute complex.  Reactions were performed at 22°C and 37°C.  
Equilibrium constants consistent with previously reported values and reaction rates were 
determined for all reactions tested except cyclosporine A.  Second, I developed a mathematical 
model describing the removal of albumin bound solutes using BSD that incorporates albumin-
solute reaction kinetics.  Previous BSD models focused on the amount of binder in the dialysate, 
ultrafiltration, and the use of solid adsorbents.  The new model relaxes the assumption of 
reaction equilibrium built into previous BSD models.  For a given equilibrium binding constant 
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 v 
and set of mass transport parameters, the model was solved for several reaction rates.  In all 
cases tested, the equilibrium BSD model overestimated removal compared to the kinetic model, 
but the kinetic model displayed greater numerical instability.  A third project explored methods 
to direct visualize protein deposition in and on commercial dialysis membranes during use.  A 
novel slide dialyzer design incorporating commercial renal dialyzer membranes was developed 
and tested. 
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1.0  INTRODUCTION 
Liver disease and liver failure remain medically intransigent in the United States and abroad and 
are responsible for many deaths each year.  Whether acute fulminant liver failure or acute 
decompensation of function on chronic liver disease, orthotopic liver transplantation (OLTx) is 
the only treatment that has been proven effective for acute liver failure.[1-3]  Despite the success 
of liver transplantation surgery, many patients die while waiting for a liver to become available.  
At any given time approximately 16,000 people are on the waiting list for a liver, but only 6319, 
6320, and 6291 transplants were performed in 2008, 2009, and 2010 respectively.  During the 
years 2000 – 2010 between 1500 and 2000 people per year have died while waiting for liver 
transplantation.[4]  The lack of treatment alternatives and the number of deaths attributed to liver 
failure argue for a need for new treatment methods to bridge patients to transplant or recovery. 
Several artificial and bioartificial (BAL) liver support systems have undergone preclinical 
and clinical evaluation with varying levels of success. BAL detoxification systems use liver cells 
cultured in a bioreactor to treat the patient’s blood in an extracorporeal circuit.  Cell-based 
therapy is perceived to have the ability to replace part of the metabolic and synthetic function 
normally seen in the liver, but several hurdles have prevented cell-based therapy from gaining 
widespread acceptance (including cell source, seeding or encapsulation matrix, and oxygenation 
method). [3, 5-9] 
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Non-biological artificial liver support systems (ALSS) have the potential to provide a 
new standard in the treatment of liver failure.  ALSS treats a patient’s blood in an extracorporeal 
circuit using dialysis, solid state adsorbents, or both.  ALSS utilizing solid state adsorbents, such 
as HemoCleanse–DT (also referred to as Biologic-DT, Liver Dialysis Unit or the Unit) 
(HemoCleanse, Lafayette, Indiana, USA) and the Prometheus system (Fresenius Medical Care, 
Bad Homburg, Germany) use activated carbon, neutral polymer adsorbents, charged exchange 
resins, or combinations of adsorbents as a sink for the removal of molecules typically cleared by 
the liver.[10-13]  Solid state adsorbent systems have been clinically shown to improve patient 
blood chemistries, but have not been proven to improve patient survival in randomized 
prospective trials.[3, 6, 7, 14, 15] 
Albumin dialysis, or more generally bound solute dialysis (BSD), as practiced by the 
Molecular Adsorbent Recycling System (MARS) (Gambro AB, Stockholm, Sweden) and single 
pass albumin dialysis (SPAD), has shown proof of principal in the clinical setting.  In vitro and 
clinical tests have shown both MARS and SPAD capable of increasing the rate of removal of 
solutes refractory to aqueous dialysis by four-fold or more over conventional intensive care unit 
(ICU) dialysis methods.[3, 7, 16-23] 
BSD systems are targeted toward the removal of solutes that are bound to proteins or 
other carriers in the blood, primarily albumin, that are normally metabolized and removed by the 
liver and that cannot be removed by conventional aqueous dialysis and other ICU methods.[6, 
24]  The removal of such bound solutes has the potential to reduce further liver and kidney 
damage due to the persistence of higher than normal concentrations of protein bound solutes.  
Unfortunately, the current BSD methods, MARS and SPAD, were heuristically designed and are 
poorly characterized.  Application of engineering principles to characterize the thermodynamics, 
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kinetics, and transport phenomena involved in BSD can be used to answer many of the basic 
questions involved in making BSD an effective treatment approach. 
1.1 THE HUMAN LIVER 
The liver is the largest human internal organ.  The liver accounts for approximately 3.8% of a 
newborn’s body mass and approximately 2% of the body mass of a typical adult.[25]  The liver 
is located toward the right side of the body just under the diaphragm, and is roughly divided into 
four lobes.  The classical description of the division of the lobes, based on the topography of the 
liver, has been replaced by divisions based on the blood flow through the liver and the ability to 
surgically resect parts of the liver.  The blood flow to the liver is fed by two vessels, the portal 
vein and the hepatic artery.  The portal vein accounts for approximately two thirds of the flow 
into the liver.  The portal vein is fed by the absorptive surfaces of the digestive tract.  All 
ingested and absorbed drugs, nutrients, and toxins therefore pass through the liver before 
entering the systemic circulation.  The hepatic artery accounts for the remaining third of the 
blood supply to the liver, and provides oxygenated blood the liver.  Blood on its way to the 
systemic circulation leaves the liver via the hepatic vein which joins the inferior vena cava on its 
way to the heart.[26, 27] 
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Figure 1.1.  Schematic representation of the lobule concept of the histological arrangement of the liver.  The 
lobule concept of the histological arrangement of the liver consists of hexagonal plates of hepatocytes with a 
central vein at the center of the lobule.  Three to six portal triads feed into each lobule.[6, 26-28] 
 
The cellular anatomy (histological organization) of the liver is arranged into regular 
functional subunits.  The architecture of the liver’s subunits are described as either lobules or 
acini.  A lobule is a hexagonal construct with a portal triad (a bile duct, a branch of the hepatic 
artery, and a branch of the portal vein) at three to six of its corners and a central vein at its center 
(Figure 1.1).  The central vein is a branch of one of the hepatic veins.  Blood vessels running 
through the portal tract connect the portal triads at either end of the portal tract to each other, and 
the blood vessels in the portal tract branch into sinusoids lined with hepatocytes as the blood 
flows to the central vein.  About 70% of a hepatocyte’s surface faces the sinusoids and about 
15% face bile canaliculi (branches of the bile duct).  While this description based on the lobule 
structure has the central vein at the center of each subunit, the acinus view has the portal triad at 
the center of a roughly circular complex acinus with three central veins around its edges (Figure 
1.2).[6, 26-28] 
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Figure 1.2.  Schematic representation of the acinus concept of the histological arrangement of the liver.  The 
acinus concept of the histological arrangement of the liver consists of two portal triads and the portal tract 
that runs between them at the center and a central vein at the ends (dotted rhombus).  Blood vessels run 
between the portal triads, and blood flows through the hepatocytes as the blood flows between the portal tract 
on the way to the central vein.  A complex acinus consists of three adjacent acini (dotted circle).[6, 26-28] 
 
The liver is connected to the digestive tract by the bile canaliculi and bile ducts.  Bile is a 
solution of metabolic wastes and cholesterol derived salts called bile acids (or bile salts).  Bile 
produced by the hepatocytes flows into the bile canaliculi, into the bile ducts, and is either fed 
into the intestinal lumen or stored in the gallbladder.  The main function of bile (other than as 
metabolic waste) is to buffer the mixture of partially digested food and digestive fluids (chyme) 
as it leaves the stomach and to facilitate the action of digestive enzymes.[26-28] 
   The metabolic and synthetic functions of the liver are numerous.  The liver performs first 
pass (and subsequent) metabolism on all drugs and nutrients from the portal drainage of the 
digestive tract before they become accessible to the rest of the body.  Many endogenous 
metabolites and waste products as well as exogenous compounds are modified and removed by 
the liver, particularly compounds that are poorly soluble and not removed by the kidneys.  The 
metabolism and removal of compounds by the liver frequently involves the action of low 
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specificity enzymes to chemically modify the compounds to make them more polar through the 
addition of charged groups.  Making a molecule more polar has the effect of making it more 
soluble in water and also makes it more difficult for the molecule to cross the hydrophobic 
membranes of cells.  Although the chemical modification of compound by the liver is meant to 
detoxify and make compounds more easily removable from the circulation, it also has the 
potential to produce toxic metabolites.  Acetaminophen (also called N-acetyl-para-aminophenol 
(APAP), Tylenol®, or paracetamol) is a common analgesic that is sold in the United States as a 
pain killer and is also found in many drug formulations including over the counter cold remedies 
and the prescription narcotics Percocet® and Vicodin®.  Most of the acetaminophen that is 
ingested by an individual will be metabolized by the glucuronidation pathway producing 
glucuronic acid.  Small amounts of acetaminophen are metabolized by cytochrome P-450s to 
produce N-acetyl-p-benzoquinone imine (NAPQI).  Most of the NAPQI that is produced is then 
conjugated with glutathione, but once glutathione is depleted the remainder reacts with proteins 
and nucleic acids causing liver cell death.  In cases of extreme overdoses, if the person taking the 
drug has a glutathione deficiency, such as happens with alcoholics, or if the drug is taken 
concurrently with alcohol, NAPQI will be produced in larger amounts and cannot be removed.  
NAPQI persisting in high concentrations causes a large amount of liver cell death, and the high 
degree of liver cell death can lead ultimately to acute liver failure.  Acetaminophen overdosing is 
the leading cause of acute liver failure in the US accounting for nearly 50% of all ALF cases.[29, 
30] 
The liver has many functions in addition to the metabolism of endogenous and exogenous 
compounds.  The conversion of glucose to glycogen and back again is performed by the liver.  
The production of a number of serum proteins is performed by the liver, including clotting 
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factors and serum albumin.  Although this is hardly an all-inclusive list, it highlights the varied 
functions of the liver.[6, 26-28] 
1.2 LIVER FAILURE 
Liver failure is characterized by the inability of the liver to perform normal metabolic and 
synthetic functions at a level that is necessary to sustain life.  Liver failure can be the result of 
either an acute insult such as poisoning or drug overdose (termed fulminant or acute liver failure 
(ALF), and defined as sudden onset of liver failure of less than eight weeks post insult with no 
prior history of liver disease) or the end result of an underlying disease state such as hepatitis C 
(HepC) or alcoholism (acute-on-chronic liver failure (ACLF), long term history of liver disease).  
Liver failure is often broken down to further define the etiology (fatty liver disease, viral 
hepatitis, alcoholic or nonalcoholic cirrhosis, and acute drug intoxication, for example).  Despite 
the range of causal factors associated with liver failure, the presentation of liver failure follows a 
fairly well defined progression (including elevated blood bilirubin and bile acid concentrations, 
renal dysfunction, and hepatic encephalopathy).[6, 26-28, 31-33] 
1.3 LIVER TRANSPLANTATION 
Better critical care management methods for ALF and ACLF patients have improved patient 
survival rates without transplantation (100% mortality 50 years ago compared to 40-60% 
mortality now depending on etiology).  In many cases standard medical therapy is not sufficient 
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for patients to recover, and the patients require liver transplantation.[34-37]  The first human 
liver transplantations were performed in 1963 and early 1964 on seven critically ill patients (five 
by Starzl at the University of Colorado, one in Boston, and one in Paris).  None of the seven 
lived more than three months.  The transplantation by Starzl in July 1967 was the first one year 
survival of a liver graft recipient.  Liver transplantation was considered experimental until the 
introduction of the immunosuppressant drug cyclosporine A (FDA approved in 1983), leading to 
a 5 year survival exceeding 50%.  The approval of the immunosuppressant drug tacrolimus (also 
known as FK506) (Astellas Pharma, Inc., Tokyo, Japan) in 1994 along with improved organ 
preservation techniques has led to a current one-year survival rate for liver transplantation of 85-
90% (depending on the underlying etiology).[33, 34, 38]   
Regardless of the improvements that have been achieved in recipient survival, many 
patients still die waiting for liver transplantation.  Many patients in need of transplantation never 
receive a liver owing to the lack of livers available for transplantation.  Of those patients that do 
receive a liver, about 8% require re-transplantation.[33]  Most transplantation is done using 
whole or partial (referred to as split liver transplantation) deceased donor (cadaveric) livers.  The 
allocation of cadaveric livers that are obtained for transplantation is performed by the United 
Network for Organ Sharing (UNOS).[33]  Patients that are most in need of liver transplantation 
surgery are prioritized using the Model for End-Stage Liver Disease (MELD).  The MELD is a 
prognostic scoring method that has been shown to predict the survival of patients in liver failure.  
The prognostic scoring method prioritizes the allocation of livers to patients that are most likely 
to die without transplantation, rather than the patients that have been on the waiting list for liver 
transplantation the longest.  UNOS uses MELD scoring to prioritize liver transplantation for 
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patients older than 12 years of age and the Pediatric End-Stage Liver Disease (PELD) scoring for 
patients 11 and younger. 
Living donor liver transplantation (LDLT) is when part of a living donor’s liver is given 
to the recipient.  Given the liver’s ability to regenerate, a significant portion of the donor’s liver 
can be removed without permanent detriment to the donor.  LDLT is an especially important 
option for small pediatric patients and patients that have been ruled out as candidates for liver 
transplantation for one reason or another based on the current deceased donor liver allocation 
system.  Although patient survival is better with LDLT than with cadaveric liver transplantation, 
the LDLT procedure creates risk to both donor and recipient, and both require support post-
transplant.[34, 39]  
1.4 ARTIFICIAL LIVER SUPPORT 
The lack of an alternative to liver transplantation and supportive care for the treatment of liver 
failure has argued for the development of new therapies to bridge liver failure patients to either 
recovery or transplantation and to support patients post transplantation.  Extracorporeal liver 
support systems have been introduced as alternatives to standard medical therapy.  Several bio- 
and mechanical artificial liver support systems have undergone preclinical and clinical 
evaluation with varying levels of success.  Extracorporeal liver support systems can be lumped 
into two categories: those that contain cells (bioartificial liver support system, BLSS) and those 
that do not (artificial liver support system, ALSS). 
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1.4.1 Bioartificial Liver Support Systems 
Bioartificial liver support systems (BLSSs) have the potential to provide metabolic and synthetic 
support that standard medical therapy alone cannot provide.  In a BLSS, liver cells are cultured 
in a bioreactor, called a bioartificial liver (BAL).  As the patient’s blood or plasma flows through 
the BAL in an extracorporeal circuit, the cells contained in the bioreactor perform some portion 
of their normal (or possibly altered and abnormal) metabolic and synthetic processes on the 
patient’s blood.  Several BLSS configurations have undergone some degree of preclinical and 
clinical evaluation, but a number of hurdles have prevented cell-based therapy from gaining 
widespread acceptance (including cell source, seeding or encapsulation matrix and method, and 
oxygenation method).  Although proof of principal has been shown by these trials, no BLSS 
device has been approved for use by the FDA.[3, 5-9, 14, 15, 40] 
1.4.2 Non-biological Artificial Liver Support System 
Non-biological artificial liver support systems (ALSS) have the potential to provide non-
metabolic, non-synthetic, support to the patient at a substantially lower risk and cost than current 
BLSS.[7, 14, 15, 20]  Systems have been developed that use solid state binders such as activated 
carbon or exchange resins (ionic, neutral, or both), but most research to date has focused on 
albumin dialysis systems.  Both albumin dialysis and solid state sorption can be termed bound 
solute dialysis (BSD).  BSD is the use of a high affinity binder on the sweep fluid side of a 
dialysis system to increase the rate of removal of albumin bound solutes from the patient’s blood.  
The basic medical hypothesis underlying the use of BSD systems is that the removal of albumin 
bound solutes that are normally metabolized and removed by the liver will mitigate further liver 
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and other organ damage from toxins and metabolites persisting in higher than safe 
concentrations.[6, 24] 
1.4.3 Bound solute dialysis systems using solid state adsorbents 
BSD systems utilizing solid state adsorbents have been developed using activated carbon, 
synthetic and natural resins, combinations of carbon and resin adsorbents, combinations of 
soluble adsorbents (albumin dialysis) and solid state adsorbents (e.g. MARS), and combinations 
of bioreactors and solid state adsorbents. 
Ash et al have developed systems based on sorption suspension dialysis.  The 
HemoCleanse – DT (also referred to as Biologic-DT, Liver Dialysis Unit or the Unit, 
HemoCleanse, Lafayette, Indiana, USA) and the HemoCleanse – DTPF use finely divided 
activated carbon as the binding agent.  The patient’s blood passes on one side of a 
semipermeable dialysis membrane while dialysate containing finely divided activated carbon 
flows through the other side of the dialysis membrane (Figure 1.3).  Conflicting reports exist as 
to whether the carbon containing dialysate stream is recirculated or is single pass through the 
dialyzer.[3, 6, 10, 11, 14] 
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Figure 1.3.  Schematic of the HemoCleanse-DT (also called The Unit for liver detoxification or Biologic DT).  
The patient’s blood flows across one side of a flat plate dialyzer and a suspension of finely divided charcoal 
adsorbent is circulated on the other side of the dialyzer.[10, 11] 
 
The Prometheus system (Fresenius Medical Care, Bad Homburg, Germany) passes the 
patient’s blood through a plasma filter, and the plasma stream is run over two adsorbent columns 
(containing neutral resin and an anion exchanger) (Figure 1.4).  After passing through the two 
adsorption columns, the plasma is recombined with the patient’s blood in the extracorporeal 
circuit, and the patient’s blood is sent through a conventional aqueous dialyzer.  The Prometheus 
system has not been well evaluated in clinical trials.[12, 13, 41, 42] 
 
 
Figure 1.4.  Schematic of the Prometheus system.  The original design (fractionated plasma separation and 
adsorption (FPSA)) had the dialyzer in the secondary loop after the two adsorption columns.[41] 
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2.0  ALBUMIN DIALYSIS 
Albumin dialysis uses an albumin solution on the sweep fluid side of a dialysis system as a sink 
for toxins and metabolites that will bind to albumin and that are refractory to removal by 
conventional dialysis.  The basic medical hypothesis underlying the use of albumin dialysis 
systems (and all BSD systems) is that the removal of protein bound solutes normally metabolized 
and removed by the liver and that cannot be removed by conventional detoxification methods has 
the potential to reduce further liver and kidney damage from protein bound solutes persisting at 
higher than normal concentrations.  Current approaches to albumin dialysis (the molecular 
adsorbent re-circulating system (MARS) and single pass albumin dialysis (SPAD)) have not 
been well characterized.  Application of engineering principles to characterize the 
thermodynamics, kinetics, and transport phenomena involved in albumin dialysis can be used to 
answer many of the basic questions involved in making albumin dialysis an effective treatment 
option. 
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2.1 THERMODYNAMICS OF BOUND SOLUTE DIALYSIS 
Solute molecules, S, complex with a site on the binder (albumin), A, to form a binder-solute 
complex according to the reaction 
 
a
d
k
k
S A S A+ •          Equation 2.1 
 
ka (L mol-1 s-1) and kd (s-1) are the rate constants for solute-binder complex formation and for the 
dissociation of the complex, respectively.  The equilibrium affinity binding constant is given by 
 
,
, ,
S A eqa
B
d S eq A eq
CkK
k C C
•= =           Equation 2.2 
 
KB (L mol-1) is the equilibrium binding constant, and Ci,eq (mol L-1) is the concentration of 
species i when the system is at equilibrium.  Although the reactions are presented here as 1:1 
binding, that is not necessarily the case.  Albumin has more than one binding site (of varying 
affinity) for many molecules.  Albumin can also bind several different molecules at various sites 
at the same time.[43]  Many chemical species that are typically removed or metabolized by the 
liver have an extremely high affinity binding constant with albumin, making them refractory to 
removal by conventional dialysis.  The albumin affinity binding constants for several compounds 
that are of interest in the modeling or treatment of liver failure or in the in vitro testing of 
artificial liver support systems are presented in Table 2.1.  Compounds with affinity binding 
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constants greater than KB = 103 L mol-1 are considered refractory to conventional aqueous 
dialysis.[18, 19, 44] 
 
Table 2.1.  Human albumin-solute affinity binding constants.[43, 45] 
      Binding constant, KB (L mol-1) 
Solute   Primary Site Secondary Site 
Bilirubin 
 
1.5 - 9.5 x 10
7 0.3 - 1.01 x 107 
Bile Acids 
   
 
Lithocholate 20.0 x 104 
 
 
Chenodeoxycholate 5.5 x 104 
 
 
Deoxycholate 4 x 104 
 Copper (II) 
 
1.5 x 10
16 
 Long-chain fatty acids ~1-70 x 107 
 Exogenous Compounds and Drugs 
 
 
Salicylate 
 
1.9 x 10
5 
 
 
Warfarin 
 
3.3 x 10
5 
 
 
Digitoxin 
 
0.4 x 10
5 
 
 
Phenol Red 2.8 x 104 
  Ibuprofen   2.7 x 106   
 
A dialysis cartridge consists of a bundle of semipermeable fibers encased in a hollow 
tube (shell) (Figure 2.1).  The fibers are potted into place at either end with impermeable glue.  A 
distribution cap at the blood inlet divides the blood flow between the fibers, and a cap at the 
outlet collects the blood flow from the fiber bundle.  The blood flow is then returned to the 
patient.  In conventional aqueous dialysis, blood flows on one side of a semipermeable 
membrane while dialysate solution (a buffered crystalloid solution that contains concentrations 
of salts and glucose similar to the plasma of a healthy patient) flows on the other side of the 
membrane countercurrent to the blood.  Solutes that are at a higher concentration on one side of 
the membrane than the other, and that are smaller than the molecular weight cutoff of the dialysis 
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membrane, will diffuse down their concentration gradient into the other solution.  The 
concentrations in the dialysate solution are typically set to retain physiological levels of salt, and 
remove excess salts, urea, and creatinine (compounds normally removed by the kidneys).  In 
some cases a transmembrane pressure gradient is maintained to remove water by ultrafiltration.  
The albumin molecule and albumin-solute complexes in a patient’s blood are too large to pass 
through a typical dialysis membrane regardless of whether transport occurs by convection or 
diffusion. 
 
 
Figure 2.1.  Schematic of a hollow fiber renal dialysis cartridge.  Blood enters a manifold that divides the flow 
into the inner lumen of the many hollow fibers encased in the dialyzer.  Fresh dialysate enters the shell space 
of the dialyzer and flows around the outside of the fibers countercurrent to the blood flow.  Molecules that 
are smaller than the pore size of the fibers will diffuse down their concentration gradients from one stream to 
the other.  Bulk fluid transport (ultrafiltration) can occur by maintaining a pressure gradient across the fiber 
wall. 
 
Unbound solutes that are smaller than the molecular weight cutoff of the dialysis 
membrane can be removed by aqueous dialysis.  The difference in free solute concentration 
across the dialysis membrane provides the driving force for diffusion, but the free concentration 
of tightly bound solutes is so small that the removal rate is too slow to be effective for the 
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removal of solutes of concern in the treatment of liver failure.[18, 19, 44]  Additionally, the 
driving force (the free solute concentration difference) is further reduced once a small amount of 
the solute has passed across the membrane.  The equilibrium free concentration of a solute can 
be calculated from the total concentrations of the solute and the binder and the binding constant 
for the binder solute complex.  The total concentration of the solute and binder are related to the 
free concentration of binder and solute and the concentration of the complex by mass balance. 
 
,S total S S AC C C •= +                                                                                                              Equation 2.3 
,A total A S AC C C •= +          Equation 2.4 
 
The concentrations of unbound solute can be calculated by combining Equation 2.2, 
Equation2.3, and Equation 2.4. 
 
2
, , ,(1 ) 0B S B A total B S total S S totalK C K C K C C C+ + − − =      Equation 2.5 
 
Since only one solution for this quadratic equation makes physical sense Equation 2.5 can be 
solved analytically for the free solute concentration, CS.  
 
2
, , , , ,
1 ( ) 1 1 ( ) 4
2S B S total A total B A total S total B S totalB
C K C C K C C K C
K
  = − − + + − +   
 Equation 2.6 
 
At concentrations of albumin and bilirubin typical for liver failure, CA,total=0.6x10-3 mol L-1 and 
CS,total=0.3x10-3 mol L-1, respectively, the free concentration of bilirubin (KB ~107 L mol-1) is 
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CS=0.2x10-6 mol L-1 (three orders of magnitude lower than the total concentration).[44]  
Minimizing the free solute concentration on the dialysate side of the membrane maximizes the 
concentration gradient, thereby maximizing the rate of solute removal from the patient.  
Reducing the dialysate side free solute concentration can be accomplished by either increasing 
the flow rate of the dialysate stream, or by introducing a binder such as albumin to the dialysate 
side of the membrane.  With a molecule that is as tightly albumin bound as bilirubin, little 
additional benefit to the rate of solute flux is achieved once a blood to dialysate albumin 
concentration ratio of as little as (CA,total)D/(CA,total)B = 0.04 ((CA,total)D and (CA,total)B are the 
patient’s blood and the dialysate albumin concentrations respectively).  Significantly higher 
albumin concentrations are required to reach the theoretical maximum removal rate for less 
tightly bound molecules.  The increase in removal rate (the impact of adding albumin to the 
dialysate) is greater for more tightly albumin bound molecules than for less tightly albumin 
bound molecules.[18, 19, 44] 
2.2 THE MOLECULAR ADSORBENT RECIRCULATING SYSTEM (MARS) 
The Molecular Adsorbent Recirculating System (MARS) (Figure 2.2) is the ALSS that has 
received the most attention from researchers and clinicians, including many publications on 
clinical trials and case studies, in vitro tests, review articles, and theoretical analyses.  MARS is a 
closed loop hybrid albumin dialysis/solid state adsorbent system.  The patient’s blood is perfused 
through a proprietary dialyzer countercurrent to a recirculating stream of albumin containing 
dialysate solution.  The MARS dialyzer has a polysulfone membrane with a sieving coefficient 
of <1% for albumin.[46]  The dialysis cartridge is pre-primed with 10% (1% is equivalent to 1 g 
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dL-1 or 10 g L-1) human albumin for 1 hour prior to use.  A passivation step with albumin to 
reduce thrombosis is not unusual with extracorporeal circuits, but in the case of MARS the 
pretreatment is meant to impregnate the dialysis membrane with albumin, not to passivate the 
surfaces in the circuit.  Solutes that are smaller than the molecular weight cutoff of the 
membrane transit out of the patient’s blood, through the dialyzer membrane, and enter the 
recirculating albumin containing dialysate stream.  The albumin concentration in the 
recirculating dialysate stream varies in the literature from 5% to 20%.  The dialysate stream then 
passes through an aqueous dialyzer and two adsorption columns that are meant to “regenerate” 
the albumin stream by removing solutes that were stripped from the blood.   
 
 
Figure 2.2.  Schematic of the Molecular Adsorbent Recirculating System (MARS).  The patient’s blood passes 
on one side of a proprietary dialyzer that is impermeable to albumin, and the “cleaned” blood is then 
returned to the patient.  Solutes (both albumin bound and water soluble) transit the dialyzer membrane to a 
recirculating albumin enriched dialysate stream.  The albumin solution then passes through an aqueous 
dialyzer and two adsorption columns to remove the solutes that were picked up from the patient’s blood.[41] 
 
 Many case studies, small randomized clinical trials, numerous review articles, and several 
in vitro experiments with the MARS system have been published.  Some of the trials and case 
 20 
studies using MARS reported reductions of biochemical markers such as blood concentrations of 
bilirubin and creatinine and improvement in hepatic encephalopathy.   
One of the earliest studies with MARS randomly assigned 13 patients with hepatorenal 
syndrome (HRS) to receive either MARS (n=8) or standard medical therapy (SMT) (n=5).  A 
significant improvement in survival was observed (37.5% vs. 0% after 7 days of treatment for 
MARS and SMT respectively).  MARS therapy also resulted in reductions to biochemical 
markers (including improvements in serum bilirubin and creatinine levels for MARS but not 
SMT), and increases in mean arterial pressure (MAP) where the control group had a further 
decrease in MAP over the study period.[47]  A later larger randomized study comparing MARS 
(n=9) versus SMT (n=9) showed no difference in 7 day survival (45% in both groups) or MAP, 
but significant improvements in encephalopathy grade were seen with MARS but not SMT. 
Recent comparisons between patients treated with only standard ICU methods and 
patients treated with the MARS system as well as conventional care showed a significant 
improvement in the quality of life adjusted cost effectiveness (a measure of the expense required 
to improve the quality of life of a patient) of the ICU care of liver failure patients when MARS 
therapy was used.[48]  Despite these seemingly positive results, MARS has not been shown to 
improve patient survival, and has not been shown to be any more effective than SPAD. 
2.3 SINGLE PASS ALBUMIN DIALYSIS (SPAD) 
Single pass albumin dialysis (SPAD) uses conventional hemodialysis or hemodiafiltration 
equipment with albumin added to the dialysate solution.  With the exception of the albumin 
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added to the dialysate stream, SPAD does not require any special equipment or disposables over 
what is required for conventional renal replacement therapy.   
The patient’s blood passes countercurrent to an albumin containing dialysate in a 
conventional hemodialysis filter.  With SPAD, the albumin containing dialysate is discarded 
after it passes through the dialyzer.  Continuously supplying fresh dialysate solution maintains 
maximum diffusion gradients in the dialyzer. 
 To date little clinical data on SPAD exists, and no randomized controlled prospective 
studies have been performed using SPAD.  A patient with multi-organ failure secondary to acute 
liver failure and Wilson’s disease was successfully bridged to transplant for 59 days using 
SPAD.[17]  During the treatments significant amounts of serum copper and bilirubin were 
removed (both are tightly albumin bound and not removed well using conventional dialysis 
methods), an improvement in hepatic encephalopathy (HE) was noted, and kidney function 
normalized after several days of treatment.  Another study looked at using SPAD on three 
patients with chronic liver failure (one patient with hepatitis B and D, one patient with hepatitis 
C, and one patient with alcohol induced cirrhosis).[21]  All three patients showed improvements 
in HE and bilirubin levels.  Two of the patients were successfully bridged to liver 
transplantation, and the third patient died from sepsis after 148 days of intermittent SPAD.  A 
third case study describes the use of albumin dialysis to treat a patient with renal insufficiency 
and intrahepatic cholestasis that developed intractable pruritus.[16]  Two sessions of albumin 
dialysis were run, one using 1.85% HSA in the dialysate and one with 5.0% HSA in the 
dialysate.  The rates of removal of the tightly bound solute bilirubin were comparable for both 
albumin concentrations.  The SPAD treatments were ended after the second treatment since the 
patient’s pruritus showed no improvement.   
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More recently, a retrospective analysis was performed looking at the efficacy of SPAD 
compared to MARS.[49]  Records of patients treated with SPAD or MARS from July of 2004 to 
August of 2008 at the university hospital of Friedrich-Schiller University Jena (Jena, Germany) 
were analyzed to compare the efficacy of the two albumin dialysis methods.   MARS was 
considered by the physicians as their first choice for albumin dialysis therapy.  The hospital only 
had one MARS system, and SPAD was performed if a second patient was to be treated while the 
MARS device was in use or if the albumin dialysis therapy needed to be started outside of the 
hospitals regular day shift.  In all 57 liver failure patients were treated over the four year span.  
MARS therapy was performed 126 times and SPAD 37 times.  No significant difference in the 
efficacy or safety between the two devices was noted, but MARS was significantly more 
expensive.  The disposables cost of a single SPAD treatment was approximately €505, and the 
disposables for a MARS treatment was approximately €2270.  In addition to the four fold greater 
disposables cost, the MARS treatment requires additional equipment and labor costs. 
 Several in vitro tests of SPAD and comparisons of SPAD with MARS have been 
performed.  Awad et al. dialyzed recirculating bovine blood spiked with bilirubin against 
dialysate containing 0, 2%, or 10% albumin with a 0.3 m2 polysulfone dialyzer.[50]  The 2% 
albumin experiments had a 3.1 fold improvement in the removal rate of bilirubin over no 
albumin, and 10% albumin in the dialysate resulted in a 4.5 fold improvement in the removal rate 
of bilirubin over no albumin in the dialysate.  The creators of the MARS system performed in 
vitro testing of SPAD and MARS.[51]  Their testing showed SPAD to be more effective than 
MARS for the removal of bilirubin (KB =108 L mol-1) and sulfobromophthalein (KB = 107 L mol-
1), but MARS more effective at removing the less tightly bound glycocholic acid (KB = 103 L 
mol-1).[43]  Sauer et al. compared SPAD, MARS, and CVVHDF.  SPAD and MARS were both 
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found superior to CVVHDF at removing several albumin bound compounds, and SPAD was 
equally effective or superior to the removal capability of MARS. 
 Patzer et al. have published the only mathematical model describing the removal of 
tightly albumin bound compounds using SPAD.[18, 19, 44]  Although albumin was the binder 
used in the experimental validation of the model, the model is equally applicable to other 
binders, and was termed more generally as bound solute dialysis (BSD).  The model and 
experimental validation both indicated that dialysate albumin concentrations in excess of 1 g L-1 
will have a negligible additional impact on the removal rate of tightly albumin bound compounds 
like bilirubin.  This is in contrast to 100-200 g L-1 of albumin used in MARS therapy.   
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3.0  MOTIVATION AND SPECIFIC AIMS OF THIS STUDY 
The basic medical hypothesis underlying the use of BSD systems is that removal of solutes that 
are bound to proteins or other carriers in the blood, primarily albumin, that are normally 
metabolized and removed by the liver and that cannot be removed by conventional aqueous 
dialysis and other intensive care unit (ICU) methods will allow the albumin present in blood to 
perform its normal function (as a carrier of various molecules in the blood).  Preventing the 
buildup of albumin bound substances has the potential to mitigate further liver and kidney 
damage from albumin bound solutes persisting at higher than normal concentrations.  
Unfortunately the current BSD methods, MARS and SPAD, were heuristically designed and are 
poorly characterized.  Application of engineering principles to characterize the thermodynamics, 
kinetics, and transport phenomena involved in BSD can be used to answer many of the basic 
questions involved in making BSD an effective treatment approach. 
 Further work is needed to expand on the basic studies of BSD to identify what is 
necessary to make BSD effective and readily available for any hospital or clinic.  The research 
presented is based on the hypothesis that the nature of the kinetics of binding and unbinding of 
albumin-solute systems and the interaction of albumin with the dialysis membrane can be 
harnessed to impact the removal of solutes refractory to aqueous dialysis (including the removal 
of specific albumin bound solutes and the unwanted stripping of therapeutic drugs).  The 
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research presented is focused on improving the understanding of the use of albumin in ALSS by 
the following specific aims: 
Specific Aim 1 – Analyze the kinetics of association and dissociation of albumin-solute binding 
pairs of interest in liver failure using Biacore SPR technology.  While a significant amount of 
information in known about the equilibrium binding properties of many albumin-solute pairs, 
little is known about the reaction kinetics.  Biacore SPR can measure the kinetics of association 
and dissociation of albumin with metabolites that build up in a patient’s blood as a result of liver 
failure (e.g. bile acids) and drugs commonly used after liver transplantation (i.e. the immune 
suppressants cyclosporine A (CyA) and tacrolimus (FK506)). 
Specific Aim 2 – Develop a mathematical description of albumin dialysis taking into account the 
kinetics of the solute-binder interaction.  The equilibrium model developed by Patzer does a 
good job describing the removal of the tightly albumin bound solute bilirubin from a reservoir, 
but several phenomena cannot be captured with the simplified reaction scheme used.  Most 
notably, a model that makes use of a more complete description of the binding reactions has the 
potential to describe what happens when the rates of reaction are on the same time scale as the 
rate of transport across the dialysis membrane and what happens when there are multiple solutes 
competing for the same binder.  Such questions speak directly to whether the dialysis membranes 
and binders are appropriate for the removal of specific toxins or drugs, and what might be 
required to design membranes and binders to target specific solutes. 
Specific Aim 3 – Investigate the penetration of albumin into the wall of commercial dialysis 
fibers by developing small scale slide dialyzers to allow for the direct visualization of the 
penetration of albumin into the dialysis membrane during use.  While a cover slip window could 
be fit to a conventional dialyzer, it would not be practical to visualize the cartridge under 
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conditions that would be typical to transplant ICU procedures.  The required pumps and fluid 
reservoirs would be prohibitive in the microscopy facility.  Fibers from commercial dialyzers 
potted into small scale dialyzers designed for use on microscopes reduce space and reagent 
requirements, while still allowing for realistic flow velocities.  The ability of albumin to enter 
and deposit in the wall of some dialysis membranes during use could for better or worse impact 
the removal capability of an ALSS.  Many blood contacting devices (including MARS) have an 
albumin priming step prior to use.  The formation of a protein layer often reduces the rate of 
transport, whether by convection or diffusion, of solutes across a dialysis membrane, and 
albumin penetration and deposition could contribute transport mechanisms in addition to 
diffusion.  Diffusion is typically considered to be the main method of removal in dialysis and 
albumin dialysis procedures.    
Basic studies and mathematical modeling of the properties of albumin dialysis can be 
used to develop BSD and albumin dialysis into a cost effective treatment for patients in liver 
failure that provides sufficient support to bridge patients to OLTx or, even better, to recovery of 
liver function.    
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4.0  SPECIFIC AIM 1: SURFACE PLASMON RESONANCE MEASUREMENT OF 
THE BINDING KINETICS OF ALBUMIN WITH BILE ACIDS, BILIRUBIN, AND 
FK506 
Mathematical modeling of albumin dialysis ALSSs indicates that the strength of the interaction 
between the binder (often albumin in both the patient’s blood and in the dialysate) and the solute 
that is being removed from a patient’s blood is a determining factor in the rate of removal of a 
given solute and the increase in the removal rate over conventional hemodialysis.[44]  However, 
a paucity of information exists on the strength of the interaction between albumin and solutes of 
interest in the treatment of liver failure (pre or post liver transplantation, e.g. tacrolimus (FK506), 
bilirubin, N-acetyl-p-benzoquinone imine (NAPQI), bile acids, etc.).  Surface plasmon resonance 
(SPR) biosensor devices (i.e. Biacore AB, Uppsala, Sweden/GE Healthcare Life Sciences 
Piscataway, NJ) have the potential to provide high throughput analysis of both the kinetics and 
equilibrium binding constants of solute-albumin interactions.[52]  Biacore SPR tracks the 
association and dissociation of unlabeled reactants in real time, which allows for the 
determination of reaction rates of association and dissociation and the equilibrium binding 
constant.  Knowledge of the albumin-solute binding reaction rates and the equilibrium binding 
constant may provide an a priori method for determining whether albumin dialysis is likely to 
increase the observable rate of removal of a given solute over conventional dialysis. 
 28 
4.1 THEORY 
Binder-solute interaction:  The reaction of the binder (albumin), A, with a given solute, S, is 
typically considered a 1:1 reaction (Equation 2.1).  Although a single albumin molecule may 
bind several different molecules or several of the same molecule at the same time, most albumin-
solute interactions at concentrations typically seen physiologically can be considered to follow 
the simple 1:1 reaction scheme.[52]  The equilibrium binding (association) constant for the 
reaction in Equation 2.1 is 
 
,
, ,
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D S eq A eq
C
K
K C C
•= =
        
Equation 4.1
 
 
KB (L mol-1) and KD (mol L-1) are the association and dissociation, respectively, equilibrium 
constants for the complex, Ci (mol L-1) is the concentration of species i, and the subscript eq 
denotes a concentration at equilibrium.  The equilibrium constant can be expressed in terms of 
the association and dissociation reaction rate constants as 
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Equation 4.2
 
 
Effect of temperature variation on binding properties:  The in vitro testing of medical devices 
and the analysis of albumin binding properties is frequently done at temperatures other than 
physiological (37°C).[19, 52]  The difference in temperatures can have a dramatic effect on the 
strength of binding and kinetics of albumin-solute binding reaction rates. 
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Albumin-solute binding can be either endothermic (negative heat of reaction) or 
exothermic (positive heat of reaction).  Measurement of the equilibrium binding constant at 
multiple temperatures is needed to determine trends for a given binding pair.  Changes in the 
equilibrium binding constant as temperature changes typically follow the von’t Hoff equation 
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Equation 4.3
 
 
K1 and K2 (L mol-1) are the equilibrium association binding constants at absolute temperatures T1 
and T2 (in Kelvin, K), respectively, R (J mol-1 K-1) is the ideal gas constant, and ΔHrxn (J mol-1) is 
the heat of reaction (binding).[53]  Changes in the binding reaction rate constants with 
temperature can typically be found using the Arrhenius equation 
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where k1 and k2 are the reaction rate constants (either association or dissociation) at temperatures 
T1 and T2, respectively and Ea (J mol-1) is the activation energy.[53-55]   
Biacore surface plasmon resonance (SPR):  Biacore SPR devices track the interaction of two 
reactants in real time.  Tracking the reaction in real time provides sufficient information to 
determine both the equilibrium constant and kinetic rate constants.  Neither of the reactants 
needs to be labeled.  A Biacore CM5 sensor chip like the one used in these experiments consists 
of a glass support layer with a 50 nm thick gold layer (Figure 4.1).  An approximately 100 nm 
thick layer of carboxymethyl dextran is covalently attached to the gold surface.  One of the 
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reactants of interest is attached either covalently (as is the case with the measurements presented 
here) or by another capture method to the dextran surface.  The binding partner and buffer flow 
past the surface of the chip.  As the immobilized reactant on the surface and the binding partner 
flowing past the surface react, there is an increase in the local density at the sensor chip surface.  
The change in density at the chip surface inside of the flow chamber causes the angle of totally 
reflected light incident on the back of the chip to change.  The change in the angle of totally 
reflected light, measured in dimensionless relative response units (RU), is tracked as the SPR 
response.   
In the case of our experiments, albumin is immobilized on the sensor chip surface and the 
reacting partner (solute) flows across the chip’s surface.  The formation of the albumin-solute 
complex at the chip’s surface results in an increase in the local density and causes a change in the 
refractive index.  The increase of density at the chip surface is tracked as an increase in the SPR 
response. 
 
 
Figure 4.1.  A Biacore sensor chip consists of a glass support layer with a 50 nm thick gold layer (a).  An ~100 
nm thick layer of carboxymethyl dextran (b) is covalently attached to the gold surface.  Reactants and buffer 
flow past the surface of the chip (c).  As reactions occur at the chip surface, the angle of reflected light at the 
back of the chip changes (1 to 2 in the plot on the right). 
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 The equilibrium binding constants can be determined by fitting the equilibrium portion of 
the response curves to an independent binding site model 
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Equation 4.5 
 
Req (RU) is the equilibrium binding response, Cj (mol L-1) is the injection concentration of the 
solute sample that is flowing across the surface, and Rmax (RU) is the maximal response possible 
for the surface when it is saturated with a given solute.  For a 1:1 binding interaction i=1, and for 
multiple independent binding sites i is the number of binding sites for a given solute.[52]   
The kinetic rate constants can be determined by fitting the SPR response vs. time curves 
to the integrated reaction rate equations.  The rate equations that result in Equation 4.5, Equation 
4.6, Equation 4.7 and are provided in Appendix B.  For the association phase the integrated rate 
equation is 
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where t (s) is time, R (RU) is the transient SPR response, and Cj (mol L-1) is the injection 
concentration of the solute.  The integrated rate equation for the dissociation phase is 
 
0( )
0
dk t tR R e− −=          Equation 4.7 
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where R0 (RU) and t0 (s) are the SPR response and time, respectively, at the start of the 
dissociation phase.[56]   
4.2 METHODS 
Surface plasmon resonance analysis was performed under contract by the University of Utah’s 
Center for Biomolecular Interaction Analysis (Director Dr. D.G. Myszka) using a Biacore S51 
(Biacore AB, Uppsala, Sweden/GE Healthcare Life Sciences Piscataway, NJ).  Research grade 
CM5 sensor chips and amine coupling reagents were obtained from GE Healthcare Life Sciences 
(Piscataway, NJ).  Research grade DMSO, cholic acid, deoxycholic acid, glycocholic acid, 
bilirubin, FK506, cyclosporine A, and bovine albumin (BSA) were obtained from Sigma-Aldrich 
(St. Louis, MO).  Medical grade 25% human albumin (HSA) solution was from Baxter 
Healthcare Corporation (Westlake Village, CA). 
Biosensor analysis:  The Biacore S51 device used has hydrodynamically addressing flow cells 
that, by changing the relative flow rates of the two inlets, allow two different reaction surfaces 
and a reference surface to be located in the same flow cell (Figure 4.2).   
 
 33 
 
Figure 4.2.  The hydrodynamically addressing flow cells in the Biacore S51 device allow separate ligands to be 
isolated on the two outside detection spots by controlling the flow rates of the two inlets.  The center detection 
spot is left as a reference surface.[57] 
 
Approximately 10,000 relative response units (RU) of BSA and HSA were immobilized on two 
of the three spots of flow cell one on a CM5 sensor chip using standard amine coupling 
chemistry, and the third detection spot was left as a reference for nonspecific binding.[58]  The 
dextran surface of the sensor chip was functionalized using a 1:1 mixture of 0.1 mol L-1 1-Ethyl-
3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and 0.1 mol L-1 N-
Hydroxysuccinimide (NHS).  The functionalized surface was then incubated with the albumin 
being immobilized on the surface at a concentration of 30 μg mL-1 in sodium acetate (pH=5.2).  
Any remaining reactive amine groups on the dextran surface were then blocked with 1 mmol L-1 
ethanolamine (pH=8.0).  All three detection spots used in the experiments were functionalized 
and blocked, but no protein was isolated on detection spot 3.  Detection spot 1 and detection spot 
2 had 10,300 RU of BSA and 9,980 RU of HSA, respectively, immobilized on the dextran 
surface.  The third detection spot was used as a reference for nonspecific solute binding.  
Phosphate buffered saline (PBS, 53 mmol L-1 Na2HPO4, 12.5 mmol L-1 KH2PO4, 70 mmol L-1M 
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NaCl, pH 7.4) was used for preparing solute samples and for performing the binding 
experiments.  PBS used for binding experiments and preparing solute samples was supplemented 
with 3% DMSO.  Binding experiments for glycocholic acid, cholic acid, and deoxycholic acid 
acids were conducted at 300 μmol L-1 and nine 2-fold serial dilutions.  Less soluble compounds 
(CyA, bilirubin and FK506) were studied at 30 μmol L-1 and nine 2-fold serial dilutions.  All 
compounds were tested on HSA and BSA surfaces at 22°C and 37°C.  Each dilution was run at 
each temperature one time across each surface.  Binding curve data analysis and curve fitting 
were performed using the SCRUBBER-2 software package developed by the Center for 
Biomolecular Interaction Analysis.  The SCRUBBER-2 software uses a nonlinear least squares 
fitting method for curve fitting, but the specific numerical methods used for curve fitting and 
determining error bound for the results are proprietary. 
4.3 RESULTS 
Response versus time curves were obtained for all compounds except CyA.  CyA was insoluble 
in 3% DMSO solutions, and displayed unusually large responses (>1000 RU) that were 
indicative of aggregates of CyA binding to the surface.  SCRUBBER-2 software algorithms were 
used to zero, align, subtract the reference flow cell response, and correct the data for changes in 
the refractive index caused by the density change resulting from dissolving the solutes in DMSO 
solutions.  As the solute flows across the sensor surface an increase in the response signal is seen 
as solute is bound by the immobilized albumin at the sensor chip surface (Figure 4.3).  After the 
sample injection ends (at 30 seconds in these experiments) buffer (without the solute) flowing 
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across the sensor chip surface removes solute molecules from the reaction site as the solute-
albumin complex dissociates. 
 
 
Figure 4.3.  As buffer containing the solute (in this case bilirubin) flows across the sensor chip surface, there 
is an increase in the SPR response as solute molecules are bound by the immobilized albumin at the sensor 
chip surface (association phase).  After the sample injection ends (at 30 seconds in these experiments) the SPR 
signal decreases as buffer flowing across the sensor chip surface removes solute molecules as the solute-
albumin complex dissociates (dissociation phase). 
 
Equilibrium binding constants:  The equilibrium portions of the response versus time curves (last 
3-5 seconds of the association phase) were plotted as a function of solute injection concentration 
and fitted using the non-linear least squares fitting routine built into SCRUBBER-2  with either a 
one (bilirubin and FK506) or two (cholic acid, deoxycholic acid, and glycocholic acid) 
independent site model (Equation 4.5, Figure 4.4).  The calculated equilibrium association 
binding constants (KB) for each interaction are reported in Table 4.1 together with previously 
reported literature values for comparison.  With the exception of bilirubin, the reported binding 
constants are similar to (within an order of magnitude) those found using other more 
conventional methods.  The binding constants for bilirubin varied from reported values by 1 to 2 
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orders of magnitude.  The binding constants decreased with a temperature increase from 22°C to 
37°C with the exception of FK506, which showed a greater than ten-fold enhancement of the 
binding strength with increased temperature. 
 
Table 4.1.  Equilibrium binding constants (KB, L mol-1) for albumin/small molecule binding reactions 
obtained by fitting the equilibrium portion of SPR response curves for a binding pair at a given temperature 
to Equation 4.5.  KB1, KB2, and the Rmax values (KB1 and KB2 have separate Rmax values associated with them) 
were the adjustable parameters in the curve fits.  Detailed results with standard errors and Rmax values can be 
found in Appendix B.[43, 45, 59-61] 
   
BSA  
 
HSA  
 
Previously reported values 
   
K
B1
  KB2  
K
B1
  KB2   
K
B1
  KB2 Albumin type Temp. 
             
Bilirubin 22°C
 
 
1.03x10
6 --------- 
 
1.15x10
6 --------- 
 
1.5x10
7 1.0x106 Human --------- 
37°C 
 
8.40x10
5 --------- 
 
4.81x10
5 --------- 
 
9.5x10
7 3x106 Human 37°C 
          
FK506 22°C
 
 
1.04x10
3 --------- 
 
1.37x10
3 --------- 
 
1.5-2.5x10
3 --------- Human 22°C 
37°C 
 
1.33x10
4 --------- 
 
6.33x10
3 --------- 
 
--------- --------- --------- --------- 
          
Colic acid 22°C
 
 
8.77x10
4 5.95x103 
 
2.38x10
4 3.57x103 
 
6.8x10
4 2.8x102 Bovine 20°C 
37°C 
 
5.24x10
4 2.70x103 
 
1.56x10
4 1.99x103 
 
3.3x10
3 3x102 Human 37°C 
          
Deoxycholic 
acid 
22°C 
 
1.45x10
5 3.03x103 
 
8.62x10
4 1.82x103 
 
2.0x10
5 3x103 Bovine 20°C 
37°C 
 
1.35x10
5 3.13x103 
 
5.29x10
4 1.56x103 
 
4.0x10
4 7x102 Human 37°C 
          
Glycocholic 
acid 
22°C 
 
2.44x10
4 2.86x103 
 
2.70x10
6 2.16x103 
 
--------- --------- --------- --------- 
37°C 
 
1.67x10
4 1.61x103 
 
2.00x10
4 1.41x103 
 
2.6x10
3 4x102 Human 37°C 
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Figure 4.4.  The equilibrium binding response (points) is plotted versus concentration and curve fit (lines) 
with a one (bilirubin and FK506) or two (colic, deoxycholic, and glycocholic acids) independent site model 
(Equation 4.5).  With the exception of FK506, a higher affinity was seen at room temperature (22°C, solid 
triangles, and solid fit line) than at a more physiological temperature (37°C, open triangles and dashed fit 
line).  FK506 displayed a 10 fold higher affinity at the higher temperature.  Note that the y-axis scales are the 
same for each solute species, but differ from solute to solute. 
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Binding rate constants:  While only the equilibrium portion of the response curves were used to 
calculate the equilibrium binding constants, the entire data set for each solute/albumin pair at a 
given temperature was used to calculate the kinetic rate constants.  The response versus time 
curves were globally fit to the rate equations (Equation 4.6 and Equation 4.7) using the nonlinear 
least squares fitting routine built into SCRUBBER-2 (Figure 4.5).[62]  The rate constants (ka and 
kd) and the Rmax values were the adjustable parameters in the curve fit.  The rate constants for 
binding and unbinding (ka and kd respectively) for each interaction are presented in Table 4.2. 
 
 
Figure 4.5.  The SPR response curves (jagged curves) were fit to the rate equations (smooth lines, Equation 
4.6 and Equation 4.7) using the non-linear least squares fitting methods built into SCRUBBER-2.  The 
association (ka) and dissociation (kd) rates and maximal response (Rmax) were the adjustable parameters in the 
fit.  These are the same SPR curves presented in Figure 4.3 with the high concentration curves removed to 
restrict the binding reaction to the higher affinity binding site. 
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Table 4.2.  Association reaction rate constants, dissociation reaction rate constants, and equilibrium binding 
constants for albumin/small molecule binding reactions obtained by globally fitting SPR response curves for a 
binding pair at a given temperature to Equation4.6 and Equation 4.7.  Rmax, ka, and kd were the adjustable 
parameters in the curve fits.  The number in parentheses is the error associated with the last significant digit. 
  
BSA  
 
HSA  
  
ka (L mol
-1 s-1) kd (s
-1)   ka/kd (L mol
-1) 
 
ka (L mol
-1 s-1) kd (s
-1) ka/kd (L mol
-1) 
         
Bilirubin 
22°C 1.010(6)x105 0.0175(2) 5.8x105 
 
6.55(5)x104 0.0282(3) 2.3x106 
37°C 1.70(2)x105 0.0535(8) 3.2x106 
 
1.60(4)x105 0.128(3) 1.3x106 
         
FK506 
22°C 94.4(6) 0.0100(1) 9.4x103 
 
---------- ---------- ---------- 
37°C 9.3(2)x103 0.81(1) 1.2x105 
 
6.0(5)x103 0.60(1) 1.0x104 
         
Colic acid 22°C 1.09(3)x10
5 2.33(6) 4.7x104 
 
7.2(3)x104 4.5(2) 1.6x104 
37°C 1.10(4)x105 3.2(1) 3.4x104 
 
8.7(7)x104 6.4(5) 1.4x104 
         Deoxycholic 
acid 
22°C 1.35(1)x105 0.845(8) 1.6x105 
 
1.62(3)x105 2.09(4) 7.8x104 
37°C 1.41(1)x105 1.35(1) 1.0x105 
 
2.13(7)x105 6.1(2) 3.5x104 
         Glycocholic 
acid 
22°C 4.4(2)x104 1.77(6) 2.5x104 
 
6.1(5)x104 3.7(3) 1.6x104 
37°C 4(2)x103 2.4(1) 1.7x103 
 
1.1(8)x104 13(2) 8.5x102 
 
4.4 DISCUSSION 
Although considerable work has been done developing albumin dialysis artificial liver support 
systems of several types, no a priori method exists to determine how effectively a specific 
molecule can be removed by albumin dialysis.  Mathematical modeling of albumin dialysis has 
been shown to be predictive of the removal rate of the tightly albumin bound solute bilirubin, but 
more detailed modeling methods have been limited by the availability of information on 
albumin-solute binding properties.  Developing a proper understanding of the albumin-solute 
binding reaction kinetics is a necessary step in understanding the behavior of albumin dialysis 
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systems and developing albumin dialysis into an effective and cost effective therapy for patients 
in liver failure. 
Fitting the equilibrium SPR response at several concentrations to a one or two 
independent site model (Equation 4.5) has been shown to provide reasonable and reproducible 
binding constants for albumin-small molecule binding reactions.  Although a large degree of 
variation in reported albumin-solute binding constants is often seen as a result of the purification 
methods used in the production of the albumin, the binding constants determined here by SPR 
have been shown to agree well with other methods used to measure binding constants.[63, 64]  
Of the reacting pairs tested in these experiments, only bilirubin varied by more than an order of 
magnitude from previously reported values (Table 4.1).  The reason for the large variation in the 
binding constant for bilirubin in the experiments versus previously reported values is not known, 
but the very low aqueous solubility of bilirubin and the isomerization of bilirubin to more soluble 
forms by exposure to light may have both contributed to the difference seen in the SPR 
measurements presented here and results obtained using other methods.[65] 
To obtain kinetic rate constants, the SPR response curves for each binding pair (not just 
the equilibrium response) were globally fit to the reaction rate equations (Equation 4.6 and 
Equation 4.7).  The ability to measure the binding reaction rate constants is a necessary step 
toward developing more realistic mathematical models of albumin dialysis.  Additionally, the 
value of the equilibrium binding constant obtained by taking the ratio of the reaction rate 
constants (Equation 4.2) provides an additional check for the accuracy and validity of values for 
the equilibrium binding constants obtained using the equilibrium SPR response.  Only the values 
of the binding constants for glycocholic acid determined by the two curve fitting methods varied 
by more than an order of magnitude.  Better estimates of the equilibrium constants are not 
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necessarily determined by curve fitting the rate equations to the entire data set for a binding pair 
instead of only the equilibrium response.  When only the equilibrium SPR response is used a 
larger concentration range can be used in the curve fit allowing for the determination of 
equilibrium constants for secondary binding sites.  Higher concentration curves were removed 
from the curve fitting to determine the reaction rate constants to prevent secondary binding sites 
from contributing to the SPR response.  Global curve fitting to determine the rate constants for 
the secondary sites may be mathematically possible, but is not possible with the SCRUBBER-2 
software package used in the analysis of the data presented here.   
 Although the two temperatures used in this study do not provide enough information to 
determine general trends for changes in the reaction rates and binding constants with changes in 
temperature, it is readily evident that the temperature needs to be considered for the testing and 
operation of albumin dialysis systems.  With the exception of FK506, the tested compounds 
showed higher affinities at 22°C than at 37°C.  FK506, however, had 12.7 and 3.7 (BSA and 
HSA, respectively) fold increases in the affinity binding constants at the higher temperature.   
4.5 CONCLUSION 
Surface plasmon resonance (SPR) provides a tool for examining the properties of albumin 
binding to solutes of interest in the development of ALSS (e.g. FK506 and other drugs used post 
transplantation surgery, bile acids and other metabolites that accumulate in blood during liver 
failure, and drugs found to cause liver failure such as acetaminophen), and provides a method for 
rapid and reproducible assessment of solutes for which no binding data is available.  Albumin 
was chosen in this study because it is the principal adsorbent in both the most studied artificial 
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liver support system (MARS) and the most cost effective and readily available method of 
artificial liver support (single pass albumin dialysis, SPAD).  Drugs and metabolytes are 
frequently bound to a significant degree to albumin or other binding agents in blood.  FK506, for 
example, is principally bound to red blood cells, and a significant portion of the drug that is not 
bound to red blood cells is bound by albumin.[66]  This does not however rule out using SPR to 
determine the ability of other compounds (e.g. lipid based carriers, artificial resins, or antibodies) 
to bind a target small molecules for removal. 
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5.0  SPECIFIC AIM 2: IMPROVED MATHEMATICAL DESCRIPTION OF BSD 
Albumin dialysis, and more generally bound solute dialysis (BSD) has the potential to improve 
the care of patients in liver failure.  The current methods of BSD, the Molecular Adsorbent 
Recirculating System (MARS) and single pass albumin dialysis (SPAD) were heuristically 
designed, and have not been well characterized.  The development of a mathematical model that 
is able to predict the performance of a BSD system can be used to better define the aspects of the 
system that can be exploited to make BSD a more effective therapy for the treatment of liver 
failure.  Patzer and Bane (2003) presented a model for the removal of albumin bound solutes by 
dialysis with a sweep fluid containing a binder.[18]  The model describes the concentration 
profile in the dialysis cartridge for solutes that have fast binder-solute binding/unbinding 
reactions when compared to the rate of transport of the solute across the dialysis membrane.  In 
the Patzer model of BSD, the binder-solute binding reactions in both the patient’s blood and in 
the dialysis sweep fluid were assumed to be at equilibrium throughout the dialysis cartridge.  The 
assumption of reaction equilibrium is not necessarily correct.  The equilibrium assumption was a 
reasonable simplification considering the paucity of information on the kinetics of small and 
middle weight solutes (such as bilirubin, bile acids, middle and long chain fatty acids, phenol 
red, and salicylic acid, to name a few) binding to albumin, and the slow rates of removal that are 
seen in bound solute dialysis (BSD).  Recent advances in biosensor technology have made it 
possible to determine the reaction rate constants for albumin-solute binding reactions with 
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relative ease.  Incorporating the reaction rates into the model allows the equilibrium assumption 
built into the Patzer model of BSD to be relaxed.  A mathematical model with an improved 
description of the kinetics and mass transport involved in BSD treatment can be used to further 
describe what is necessary for BSD to become a cost effective and available treatment for 
patients with liver function insufficiencies.  The equilibrium model of BSD may be giving us an 
incomplete picture of the interaction between the kinetics of binding and unbinding and the mass 
transport of solutes across the dialysis membrane.   
Dialysis is generally performed with the therapeutic goal of removing a set of solutes that 
are present in the blood.  The solutes generally considered are those that are building up due to 
metabolic processes or acute intoxication (for example urea and salts in renal failure and 
bilirubin, drugs, or drug metabolites in liver failure).  Although many of the solutes that are of 
interest in liver and renal failure are not necessarily toxic, they may have the potential to cause 
damage by persisting in higher than typical concentrations.  High concentrations of albumin 
bound solutes in the blood of patients in liver failure prevents albumin from performing it’s 
normal function as a solute carrier in blood by saturating albumin’s binding sites.  The original 
equilibrium model presented by Patzer and the model presented here incorporating the albumin-
solute binding kinetics consider the case of solutes that are bound by albumin in the blood and 
dialysate streams, but both models are equally applicable to binders other than albumin as well as 
different binders on the blood and dialysate sides with little additional mathematical complexity.   
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5.1 METHODS 
5.1.1 Albumin-solute binding reactions  
The diffusive flux of a bound solute being removed from a patient’s blood by BSD is a three step 
process (Figure 5.1).  As blood passes through the dialyzer, free binder (albumin), A, and free 
solute, S, in the blood (subscript B) associate to form the solute-binder complex, S●A, and the 
complex dissociates into free binder and solute: 
 
( ) ( ) ( )
a
d
k
B B B
k
S A A S• +          Equation 5.1 
 
Molecules that are smaller than the molecular weight cutoff of the membrane being used will 
diffuse down their concentration gradient into the dialysate (subscript D): 
 
DB SS )()( →           Equation 5.2 
 
ka (L mol-1 s-1) and kd (s-1) are the reaction rate constants of association and dissociation, 
respectively, of the solute binder complex.  Likewise, any molecule that has a higher 
concentration in the dialysate will diffuse down its concentration gradient into the blood.  Free 
binder present on the dialysate side will react with solute crossing the membrane.    
 
( ) ( ) ( )
a
d
k
D D D
k
A S S A+ •         Equation 5.3 
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The “cleaned blood” that exits the dialyzer is then returned to the patient. 
 
 
Figure 5.1.  Schematic of the binder-solute binding reactions and diffusive solute transport in a 
countercurrent dialyzer.  As blood passes through the dialyzer, free binder, A, and free solute, S, in the blood 
(subscript B) associate to form the solute-binder complex, S●A, and the complex dissociates into free binder 
and solute.  Molecules that are smaller than the molecular weight cutoff of the membrane being used will 
diffuse down their concentration gradient into the dialysate (subscript D).  ka (L mol-1 s-1) and kd (s-1) are the 
reaction rate constants of association and dissociation, respectively, of the solute binder complex.  Free binder 
present on the dialysate side will react with solute crossing the membrane.    
5.1.2 Single solute dialyzer concentration profile  
A series of non-linear first order ordinary differential equations (ODEs) were derived to describe 
the reactions and removal of the solute and solute-albumin complex on both the blood and 
dialysate sides.  The complete derivation and non-dimensionalization scheme for the equations 
presented in this section can be found in Appendix C.  Mass balances on the blood side, subscript 
 
( ) ( ) ( )
a
d
k
B B B
k
S A A S• +
Membrane 
( ) ( ) ( )
a
d
k
D D D
k
S A A S• +
 diffusive  
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blood 
flow 
dialysate 
flow 
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B, yield non-dimensional equations describing the normalized concentration of solute, (CS
~
 )B, and 
the normalized solute binder complex, (  CSA
~
)B, as a function of position (z
~
 ) in the dialyzer. 
 
( ) 1 2( ) ( ) ( ) ( ) ( ) ( ( ) )S B S D S B SA B S B SA Bd C C C Da C Da C Cdz κ ε= − + − −

    

   Equation 5.4 
2 1
( ) ( ) ( ( ) ) ( )SA B S B SA B SA B
d C Da C C Da C
dz
ε= − −

  

     Equation 5.5 
 
Symbol definitions are provided in Table 5.1.  κ is a dimensionless mass transport constant (the 
dialyzer area-mass transport constant normalized to blood flow rate, kA/QB), Da1, the 
dissociation Damkohler number, is the ratio of the complex dissociation rate constant to the rate 
of convective throughput (VBkd/QB), Da2, the association Damkohler number, is the ratio of the 
complex association rate constant to the rate of convective throughput of solute 
(VBka/QB[(CS,total)B]in), and ε is molar ratio of albumin to bilirubin at the blood stream inlet 
((CA,total)B/[(CS,total)B]in). A mass balance on the dialysate side, subscript D, yields 
 
( ) 1 2( ) ( ) ( ) ( ) ( ) ( ( ) ))S D S B S D SA D S D SA Dd C Da DaC C C C Cdz
γ γκ βε
α α α
= − + − −
− − −

    

  Equation 5.6 
2 1( ) ( ) ( ( ) ) ( )SA D S D SA D SA D
d C Da DaC C C
dz
γ γ
βε
α α
= − −
− −

  

     Equation 5.7 
 
where γ is the ratio of the blood side volume to the dialysate side volume (VD/VB), α is the ratio 
of the dialysate side flow rate to the blood side flow rate (QD/QB), and β is the molar ratio of the 
binder (albumin) concentration in the dialysate to the concentration in the dialysate 
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((CA,total)D/(CA,total)B).  The boundary values for the blood side inlet are set to the equilibrium 
concentrations and the dialysate side inlet has clean dialysate, 
 
0~@])~[()~( == zCC inBSBS         Equation 5.8 
( ) [( ) ] @ 0SA B SA B inC C z= =           Equation 5.9 
1~@0)~( == zC DS          Equation 5.10 
( ) 0 @ 1SA DC z= =           Equation 5.11 
 
Table 5.1.  Symbol and dimensionless parameter definitions for kinetic model of bound solute dialysis. 
Parameter Meaning  Range 
CA
~
  Dimensionless concentration of binder 
 
CS
~
  Dimensionless concentration of solute 
 
CS●A
~
  Dimensionless concentration of the solute-binder complex 
 κ = kA / QB Dialyzer mass transfer/blood flow rate ratio 0.5 – 3.0 
α = QD / QB Dialysate/blood flow rate ratio 0.1 – 2.5 
Da1 = VBkd  / QB Dissociation reaction rate/blood flow rate ratio  0.33 – 600 
Da2 = VBka / (QB[(CS,total)B]in) Association reaction rate/blood flow rate ratio 1.0x102 – 1.8x106 
ε = (CA,total)B / [(CS,total)B]in Blood total albumin/incoming total solute concentration ratio 1.1 
γ = VD / VB Dialysate side/blood side volume ratio 1 
β = (CA,total)D / (CA,total)B Dialysate/blood total albumin concentration ration 0.01 – 0.5 
KB = ka / kd Equilibrium binding constant 1 – 10
6
 L mol-1 
 
 
The value of the incoming, subscript in, blood side solute and complex concentrations, [(CS
~
 )B]in 
and [(  CSA
~
)B]in, respectively, are calculated from the equilibrium binding constant, total solute 
concentration, and total albumin concentration at the blood side inlet.  For the one to one binding 
model presented here, the association equilibrium binding constant, KB (L mol-1), is defined as  
 49 
 
,
, ,
S A eqa
B
d S eq A eq
CkK
k C C
•= =         Equation 5.12 
 
The concentration of the complex, CS●A,eq (mol L-1), the solute, CS,eq, and the albumin 
concentration, CA,eq, are the concentrations at equilibrium (subscript eq).  The total solute and 
albumin concentrations (regardless of whether the reactions are at equilibrium) are given by 
 
,S total S SAC C C= +          Equation 5.13 
,A total A SAC C C= +          Equation 5.14 
  
Equation 5.4 through Equation 5.7 with boundary conditions (Equation 5.8 through Equation 
5.11) were solved with boundary value problem solver (bvp4c) in the software package 
MATLAB (The MathWorks, Inc.,Natick, MA).  The blood side inlet conditions are determined 
from the blood total concentrations of albumin and solute and the equilibrium binding constant.   
5.2 RESULTS 
In order to reduce the number of permutations of parameters to explore, the models (the original 
Patzer model of BSD and the extended kinetic description presented here) were solved at 
constant values of the total blood side albumin concentration, (CA, total)B = 40 g L-1 = 6.06x10-4 
mol L-1, the blood total albumin/incoming total solute concentration ratio, ε = 1.1, and the 
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dialysate side/blood side volume ratio, γ = 1.  A choice of Da1, KB, (CA, total)B, and ε also defines 
Da2 according to the equation 
 
2 1 ,( )B A total BDa Da K Cε=         Equation 5.15 
 
For lightly bound solutes (KB = 100), the dissociation Damkohler number, Da1, is three orders of 
magnitude greater than the association Damkohler number, Da2, (Da1/Da2 = 1500); for 
moderately bound solutes (KB= 104) the value of the dissociation Damkohler number is one order 
of magnitude smaller than the association Damkohler number (Da1/Da2 = 0.15); and for tightly 
bound solutes (KB = 106) the value of the dissociation Damkohler number is three orders of 
magnitude smaller than association Damkohler number (Da1/Da2 = 0.0015) (Figure 5.2).  
The solute concentration profile through the dialysis cartridge was solved for pairings of 
high (+) and low (-) values of the clinical range for the dialysate/blood flow rate ratio, α, and 
mass transport/blood flow rate ratio parameter, κ.  High and low values for parameters used for 
modeling are provided in Table 5.2.  For each flow rate ratio/mass transport parameter pairing, 
the models were solved for a range of the dialysate/blood albumin concentration ratios, β, and 
binding constants, KB, and for each KB value the models were solved for a range of dissociation 
Damkohler number, Da1, values (Figure 5.3, Figure 5.4, Figure 5.5, and Figure 5.6).   
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Figure 5.2.  For a given value of the equilibrium constant, KB (L mol-1), the value of Da1 was chosen and the 
value of Da2 changes according to Equation 5.15. For KB = 100 (solid line), the value of the Damkohler number 
for dissociation, Da1, is three orders of magnitude greater than the value of the Damkohler number for 
association, Da2, (Da1/Da2 = 1500), for KB= 104 the value of Da1 is one order of magnitude smaller than Da2 
(Da1/Da2 = 0.15), and for KB = 106 the value of Da1 is three orders of magnitude smaller than Da2 (Da1/Da2 = 
0.0015). 
 
Table 5.2.  Values of parameters used for kinetic modeling of bound solute dialysis.  The values for each 
parameter are chosen to reflect current CVVHD and albumin dialysis practices.  (CA,total)B and γ are held 
constant for all simulations.   
Parameter Units Low (-) High (+) 
(CA,total)B  g L-1 40 40 
β 
 
0.01 0.5 
ε 
 
1.1 1.1 
α 
 
0.1 2.5 
κ  
 
0.5 2.0 
γ 
 
1 1 
KB L mol-1 1 106 
Da1   0.1 1000 
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The single pass fractional removal, F, can be used as a metric of the removal effectiveness for a 
given set of conditions, and is defined as 
 
, ,
,
,
[( ) ] [( ) ]
1 [( ) ]
[( ) ]
S total B in S total B out
S total B out
S total B in
C C
F C
C
−
= = −       Equation 5.16 
 
The behavior of the equilibrium BSD model as a function of the dialysate side/blood side 
albumin concentration ratio, β, the relative flow rates of the dialysate to blood streams, α, and the 
mass transport rate/blood side flow rate ratio, κ, was explored in detail by Patzer et. al.  The 
fractional removals of solute for the conditions tested in this study are presented in Table 5.3, 
Table 5.5, Table 5.4, and Table 5.6.  Although the results are presented here in terms of the 
fractional removal (not the fractional removal normalized to the fractional removal under high 
flow rate dialysis without albumin present as presented by Patzer et. al.), the results obtained for 
the equilibrium model mirror those obtained by Patzer et. al.  Maximal removal was seen for 
maximum dialysate/blood flow rate ratio, α+, and maximum mass transport rate/blood flow rate 
ratio, κ+, regardless of the dialysate side/blood side albumin concentration ratio, β, present in the 
dialysate.  At the minimum dialysate/blood flow rate ratio, α-, there is a negligible difference in 
the fractional removal (< 2%) for changes in the value of the mass transport rate/blood flow rate 
ratio, κ, in the range tested.  Increasing the dialysate/blood flow rate ratio, α, regardless of the 
value of the mass transport rate/blood flow rate ratio, resulted in a large increase to the fractional 
removal.  For any given flow rate ratio/mass transport parameter pairing, the maximum removal 
was always seen for lightly bound solutes (KB = 100), and the lowest removals were seen for 
tightly bound solutes (KB = 106).  For lightly bound solutes (KB = 100) there was negligible 
improvement in the removal rate of bound solutes with the addition of albumin to the dialysate, 
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and for moderately bound solutes (KB = 104) or tightly bound solutes (KB = 106) removal rates 
are increased with increasing dialysate side albumin concentrations.  Although in general higher 
removal is seen at high dialysate/blood flow rate ratios, for tightly bound solutes (KB > 106) at 
high dialysate/blood albumin ratios (β ≥ 0.5), the system becomes insensitive to flow rate and 
becomes a function of the mass transport parameter only. 
The difference between the results obtained using the original equilibrium model of BSD 
and the results obtained using the expanded model accounting for the kinetics of the binding 
reactions can be quantified by defining the deviation, D, between the solutions of the two models 
in terms of the percent difference in the fractional removal 
 
1
,, , , , ,( )
( ) ( )
100
( )
B A total B
Equilibrium Da
Equilibrium K C
F F
D
F
β α κ ε
 −
=  
  
     Equation 5.17 
 
For determining the deviation, D, the equilibrium binding constant, KB, the dialysate/blood 
albumin ratio, β, the dialysate/blood flow rate ratio, α, and the mass transport rate/blood flow rate 
ratio, κ, were chosen, and the values of the Damkohler numbers for dissociation, Da1, and 
association, Da2, were chosen around those values.  For a given value of the equilibrium 
constant, the value of dissociation Damkohler number was chosen and the value of association 
Damkohler number is found using Equation 5.15.  Positive values of deviation indicate that the 
equilibrium model is overestimating the single pass fractional removal, and negative values 
indicate the equilibrium model underestimating single pass fractional removal.  As the value of 
deviation approaches zero, the solution of the kinetic model approaches the solution to the 
 54 
equilibrium model.  The deviation for each condition tested can be found in Table 5.3, Table 5.5, 
Table 5.4, and Table 5.6. 
 Regardless of the condition tested, the equilibrium model overestimated the single pass 
fractional removal.  The equilibrium model assumes that the rate of dissociation of the solute-
albumin complex on the blood side is fast compared to the rate that solute can transit the dialysis 
membrane and that the solute on the dialysate side is then bound at an infinitely fast rate.  In 
other words the reactions are always at equilibrium.  This is a best case scenario in that, as long 
as solute is being removed from the blood side, finite reaction rates require that the blood side is 
always free solute depleted and the dialysate side is always free solute enriched compared to 
when the binding reactions are at equilibrium (the opposite is of course true for solutes that are in 
higher concentrations on the dialysate side than on the blood side).   
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Figure 5.3.  Fractional concentration of solute as a function of dimensionless position on the blood path side of 
a countercurrent dialyzer for α=2.5 and κ=2.0 (α+ κ+) at KB =100, 104, and 106 (separated by groupings on the 
plots).  The solution to the Patzer equilibrium BSD model (solid line) over estimates the removal of solute 
compared to the kinetic model regardless of the choice of reaction rate constants (Da1=0.1 [dotted line], 
Da1=10 [dash/dot line], and Da1=1000 [dashed line]).  For a given equilibrium binding constant the kinetic 
model solution approaches the equilibrium model solution for increasing values of Da1 (i.e. the dissociation 
rate constant, kd).  The kinetic BSD model was unsolvable by the chosen numerical solution method for α=2.5, 
κ=2.0, and KB=106 for the following combinations of β and Da1:  β=0/Da1=10, β=0/Da1=1000, β=0.01/Da1=10, 
β=0.01/Da1=1000, β=0.1/Da1=1000, β=0.5/Da1=1000. 
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Figure 5.4.  Fractional concentration of solute as a function of dimensionless position on the blood path side of 
a countercurrent dialyzer for α=0.1 and κ=2.0 (α- κ+) at KB =100, 104, and 106 (separated by groupings on the 
plots).  The solution to the Patzer equilibrium BSD model (solid line) over estimates the removal of solute 
compared to the kinetic model regardless of the choice of reaction rate constants (Da1=0.1 [dotted line], 
Da1=10 [dash/dot line], and Da1=1000 [dashed line]).  For a given equilibrium binding constant the kinetic 
model solution approaches the equilibrium model solution for increasing values of Da1 (i.e. the dissociation 
rate constant, kd). The kinetic BSD model was unsolvable by the chosen numerical solution method for α=0.1, 
κ=2.0, and KB=106 for the following combinations of β and Da1:  β=0/Da1=10, β=0/Da1=1000, β=0.01/Da1=10, 
β=0.01/Da1=1000, β=0.1/Da1=1000, β=0.5/Da1=1000. 
 
 57 
0.55
0.6
0.65
0.7
0.75
0.8
0.85
0.9
0.95
1
0 0.2 0.4 0.6 0.8 1F
ra
ct
io
na
l s
ol
ut
e 
co
nc
en
tr
at
io
n
Dimensionless position in dialyzer
0.55
0.6
0.65
0.7
0.75
0.8
0.85
0.9
0.95
1
0 0.2 0.4 0.6 0.8 1
Dimensionless position in dialyzer
0.55
0.6
0.65
0.7
0.75
0.8
0.85
0.9
0.95
1
0 0.2 0.4 0.6 0.8 1
0.55
0.6
0.65
0.7
0.75
0.8
0.85
0.9
0.95
1
0 0.2 0.4 0.6 0.8 1F
ra
ct
io
na
l s
ol
ut
e 
co
nc
en
tr
at
io
n
β = 0      
α = 2.5
κ = 0.5
β = 0.01       
α = 2.5
κ = 0.5
β = 0.1       
α = 2.5
κ = 0.5
KB = 1   
KB = 104
KB = 106
β = 0.5      
α = 2.5
κ = 0.5
KB = 1   
KB = 104
KB = 106
KB = 1   
KB = 104
KB = 106
KB = 1   
KB = 104
KB = 106
 
Figure 5.5.  Fractional concentration of solute as a function of dimensionless position on the blood path side of 
a countercurrent dialyzer for α=2.5 and κ=0.5 (α+ κ-) at KB =100, 104, and 106 (separated by groupings on the 
plots).  The solution to the Patzer equilibrium BSD model (solid line) over estimates the removal of solute 
compared to the kinetic model regardless of the choice of reaction rate constants (Da1=0.1 [dotted line], 
Da1=10 [dash/dot line], and Da1=1000 [dashed line]).  For a given equilibrium binding constant the kinetic 
model solution approaches the equilibrium model solution for increasing values of Da1 (i.e. the dissociation 
rate constant, kd). The kinetic BSD model was unsolvable by the chosen numerical solution method for α=2.5, 
κ=0.5, and KB=106 for the following combinations of β and Da1:  β=0/Da1=10, β=0/Da1=1000, β=0.01/Da1=10, 
β=0.01/Da1=1000, β=0.1/Da1=1000, β=0.5/Da1=1000. 
 
 
 58 
0.88
0.9
0.92
0.94
0.96
0.98
1
0 0.2 0.4 0.6 0.8 1
Dimensionless position in dialyzer
0.88
0.9
0.92
0.94
0.96
0.98
1
0 0.2 0.4 0.6 0.8 1
0.88
0.9
0.92
0.94
0.96
0.98
1
0 0.2 0.4 0.6 0.8 1F
ra
ct
io
na
l s
ol
ut
e 
co
nc
en
tr
at
io
n
β = 0      
α = 0.1
κ = 0.5
β = 0.01       
α = 0.1
κ = 0.5
KB = 1   
KB = 104
KB = 106
β = 0.5      
α = 0.1
κ = 0.5
KB = 1   
KB = 104
KB = 106
0.88
0.9
0.92
0.94
0.96
0.98
1
0 0.2 0.4 0.6 0.8 1Fr
ac
tio
na
l s
ol
ut
e 
co
nc
en
tr
at
io
n
Dimensionless position in dialyzer
KB = 1   
KB = 104
KB = 106
β = 0.1       
α = 0.1
κ = 0.5
KB = 1   
KB = 104
KB = 106
 
Figure 5.6.  Fractional concentration of solute as a function of dimensionless position on the blood path side of 
a countercurrent dialyzer for α=0.1 and κ=0.5 (α- κ-) at KB =100, 104, and 106 (separated by groupings on the 
plots).  The solution to the Patzer equilibrium BSD model (solid line) over estimates the removal of solute 
compared to the kinetic model regardless of the choice of reaction rate constants (Da1=0.1 [dotted line], 
Da1=10 [dash/dot line], and Da1=1000 [dashed line]).  For a given equilibrium binding constant the kinetic 
model solution approaches the equilibrium model solution for increasing values of Da1 (i.e. the dissociation 
rate constant, kd). The kinetic BSD model was unsolvable by the chosen numerical solution method for α=0.1, 
κ=0.5, and KB=106 for the following combinations of β and Da1:  β=0/Da1=0.1, β=0/Da1=10, β=0/Da1=1000, 
β=0.01/Da1=10, β=0.01/Da1=1000, β=0.1/Da1=1000, β=0.5/Da1=1000. 
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Table 5.3.  Fractional removal of blood side solute and percent deviation of the fractional removal for α=2.5 
and κ=2.0 (α+ κ+) as predicted by both the kinetic BSD model and the Patzer equilibrium BSD model.  
Conditions that were unsolvable using the chosen numerical solution method are indicated with n/a.  EQ: 
equilibrium BSD model, n/a: value not available 
  
  
Fractional removal 
 
Deviation 
   
  Da1   
  
  Da1   
β KB   0.1 10 1000 EQ   0.1 10 1000 
0 100 
 
0.794 0.794 0.794 0.794 
 
0.0 0.0 0.0 
0 104 
 
0.252 0.299 0.302 0.326 
 
22.9 8.5 7.6 
0 106 
 
0.016 n/a n/a 0.020 
 
21.3 n/a n/a 
           0.01 100 
 
0.794 0.794 0.794 0.794 
 
0.0 0.0 0.0 
0.01 104 
 
0.252 0.300 0.303 0.329 
 
23.5 9.0 8.1 
0.01 106 
 
0.016 n/a n/a 0.025 
 
37.7 n/a n/a 
           0.1 100 
 
0.794 0.794 0.794 0.794 
 
0.0 0.0 0.0 
0.1 104 
 
0.252 0.306 0.312 0.349 
 
27.8 12.3 10.5 
0.1 106 
 
0.017 0.023 n/a 0.027 
 
38.8 15.9 n/a 
           0.5 100 
 
0.794 0.794 0.794 0.794 
 
0.0 0.0 0.0 
0.5 104 
 
0.252 0.325 0.336 0.380 
 
33.7 14.6 11.6 
0.5 106   0.019 0.024  n/a 0.028   32.1 14.8  n/a 
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Table 5.4.  Fractional removal of blood side solute and percent deviation of the fractional removal for α=2.5 
and κ=0.5 (α+ κ-) as predicted by both the kinetic BSD model and the Patzer equilibrium BSD model.  
Conditions that were unsolvable using the chosen numerical solution method are indicated with n/a.  EQ: 
equilibrium BSD model, n/a: value not available   
   
Fractional removal 
 
Deviation 
   
  Da1   
  
  Da1   
β KB   0.1 10 1000 EQ   0.1 10 1000 
0 100 
 
0.368 0.368 0.368 0.368 
 
0.0 0.0 0.0 
0 104 
 
0.113 0.115 0.115 0.125 
 
9.7 8.4 8.2 
0 106 
 
0.006 n/a n/a 0.007 
 
16.8 n/a n/a 
           0.01 100 
 
0.368 0.368 0.368 0.368 
 
0.0 0.0 0.0 
0.01 104 
 
0.113 0.115 0.115 0.126 
 
10.1 8.6 8.4 
0.01 106 
 
0.006 n/a n/a 0.007 
 
22.8 n/a n/a 
           0.1 100 
 
0.368 0.368 0.368 0.368 
 
0.0 0.0 0.0 
0.1 104 
 
0.113 0.116 0.117 0.129 
 
12.2 10.1 9.5 
0.1 106 
 
0.006 0.006 n/a 0.008 
 
22.5 15.8 n/a 
           0.5 100 
 
0.368 0.368 0.368 0.368 
 
0.0 0.0 0.0 
0.5 104 
 
0.113 0.118 0.120 0.133 
 
14.9 10.8 9.8 
0.5 106   0.006 0.006  n/a 0.008   19.9 15.5  n/a 
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Table 5.5.  Fractional removal of blood side solute and percent deviation of the fractional removal for α=0.1 
and κ=2.0 (α- κ+) as predicted by both the kinetic BSD model and the Patzer equilibrium BSD model.  
Conditions that were unsolvable using the chosen numerical solution method are indicated with n/a.  EQ: 
equilibrium BSD model, n/a: value not available 
   
Fractional removal 
 
Deviation 
   
  Da1   
  
  Da1   
Β KB   0.1 10 1000 EQ   0.1 10 1000 
0 100 
 
0.100 0.100 0.100 0.100 
 
0.0 0.0 0.0 
0 104 
 
0.031 0.029 0.028 0.031 
 
0.3 6.3 8.4 
0 106 
 
0.001 n/a n/a 0.002 
 
5.8 n/a n/a 
           0.01 100 
 
0.100 0.100 0.100 0.100 
 
0.0 0.0 0.0 
0.01 104 
 
0.031 0.029 0.029 0.031 
 
1.4 7.1 9.1 
0.01 106 
 
0.002 n/a n/a 0.003 
 
11.7 n/a n/a 
           0.1 100 
 
0.100 0.100 0.100 0.100 
 
0.0 0.0 0.0 
0.1 104 
 
0.034 0.033 0.032 0.038 
 
10.2 12.9 14.6 
0.1 106 
 
0.008 0.009 n/a 0.011 
 
29.0 18.7 n/a 
           0.5 100 
 
0.100 0.100 0.100 0.100 
 
0.0 0.0 0.0 
0.5 104 
 
0.046 0.049 0.048 0.065 
 
29.7 25.3 26.3 
0.5 106   0.017 0.021  n/a 0.027   37.0 19.7  n/a 
 
 
 
 
 
 
 
 
 
 
 62 
Table 5.6.  Fractional removal of blood side solute and percent deviation of the fractional removal for α=0.1 
and κ=0.5 (α- κ-) as predicted by both the kinetic BSD model and the Patzer equilibrium BSD model.  
Conditions that were unsolvable using the chosen numerical solution method are indicated with n/a.  EQ: 
equilibrium BSD model, n/a: value not available 
 
   
Fractional removal 
 
Deviation 
   
  Da1   
  
  Da1   
Β KB   0.1 10 1000 EQ   0.1 10 1000 
0 100 
 
0.099 0.099 0.099 0.099 
 
0.0 0.0 0.0 
0 104 
 
0.030 0.028 0.028 0.031 
 
1.1 7.8 8.4 
0 106 
 
n/a n/a n/a 0.002 
 
n/a n/a n/a 
           0.01 100 
 
0.099 0.099 0.099 0.099 
 
0.0 0.0 0.0 
0.01 104 
 
0.030 0.029 0.028 0.031 
 
2.4 8.5 9.2 
0.01 106 
 
0.002 n/a n/a 0.003 
 
19.8 n/a n/a 
           0.1 100 
 
0.099 0.099 0.099 0.099 
 
0.0 0.0 0.0 
0.1 104 
 
0.033 0.032 0.032 0.037 
 
12.6 14.1 14.6 
0.1 106 
 
0.005 0.005 n/a 0.007 
 
34.2 21.8 n/a 
           0.5 100 
 
0.099 0.099 0.099 0.099 
 
0.0 0.0 0.0 
0.5 104 
 
0.041 0.046 0.046 0.062 
 
34.1 25.5 25.7 
0.5 106   0.006 0.006 n/a  0.007   21.6 16.6  n/a 
 
 
Lightly bound solutes (KB = 100):  There was essentially no deviation (<1%) for lightly bound 
solutes (KB = 100, Da1/Da2 = 1500) regardless of the other conditions tested.  With lightly bound 
solutes the rate that the solute-albumin complex on the blood side can dissociate is sufficient to 
keep up with the rate that free solute can be removed from the blood side regardless of the mass 
transport parameter or dialysate/blood flow rate ratio.  As was expected based on the results of 
Patzer et. al., the addition of albumin to the dialysate side (increasing β) had no practical impact 
on the rate of solute removal from the blood side.  In the case of weakly bound solutes the 
system is essentially controlled by the mass transport properties of the dialysis membrane and the 
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convective flow rates of blood and dialysate.  Since the binding reactions play such a minor role 
in the removal, existing dialysis models that do not consider solute-albumin reactions are 
adequate to describe removal of such weakly bound solutes. 
Moderately bound solutes (KB = 104):  With less albumin in the dialysate than what is required 
to maximize the removal rate (β = 0, 0.01, or 0.1) the magnitude of the deviation decreases with 
increasing reaction rates (Da1 and Da2) for high dialysate/blood flow rate ratio (regardless of the 
value of the mass transport parameter), but the value of deviation increases (lower removal rates) 
with increasing reaction rates (Da1 and Da2) for low dialysate/blood flow rate ratio (regardless of 
the value of the mass transport parameter).  This indicates that there is less benefit to higher 
reaction rates if there is insufficient sweep fluid or albumin present to depress the dialysate side 
free solute concentration. For cases of either high dialysate albumin concentrations or high 
dialysate/blood flow rate ratio, deviation decreases with higher reaction rates (Da1 and Da2). 
Tightly bound solutes (KB = 106):  All of the simulations performed in this study were solved 
using a MATLAB boundary value problem solver (bvp4c).  All equilibrium (Patzer model) BSD 
simulations ran and provided a numerical solution without error, but kinetic BSD simulations 
with tightly bound solutes (KB = 106) had an apparent numerical instability.  The numerical 
solution diverged from the boundary conditions at higher values of the Damkohler numbers (Da1 
and Da2).   Although this instability may be related to the initial guess used in the simulation, 
attempts to use the solution to simulations performed at low vales of Da1 and Da2 as the initial 
guess for simulations at higher Da1 and Da2 did not result in an improved ability for the solver to 
reach a stable solution. 
General trends for tightly bound solutes were difficult to establish given that the 
simulations were unstable and would not solve at higher values of reaction rates (Da1 and Da2) 
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or low values of the dialysate/blood albumin concentration ratio, β.  Overall, deviation was 
higher for tightly bound solutes (KB=106, Da1/Da2 = 0.0015) than for less tightly bound solutes 
(KB=104, Da1/Da2 = 0.15).  The higher deviation is slightly misleading however in that fractional 
removal values are so low for tightly bound solutes.  For tightly bound solutes the deviation 
ranged from 6% to 39% with a difference in fractional removal ranging from 0.0001 to 0.01, 
respectively, as opposed to deviation for moderately bound solutes ranging from 0.3% to 34% 
with a difference in fractional removal ranging from 0.0001 to 0.13 (a much bigger difference in 
the actual removal rate), respectively.  For higher dialysate side albumin concentrations, β=0.1 or 
0.5, the deviation decreased with increasing reaction rates (Da1=0.1 to 10) for all flow rate/mass 
transport parameter (α and κ) pairs.  At slow reaction rates (Da1=0.1) the deviation was highest 
for high flow rates and high mass transport parameter (α+ κ+), but at higher reaction rates 
(Da1=10) the value of deviation was higher for low dialysate/blood flow rate ratios (α-) 
regardless of the value of the mass transport parameter, κ. 
5.3 DISCUSSION 
A model of BSD that accurately represents the physics of the system is important to developing 
an understanding of what impact system properties and operating parameters have on the 
removal rates that can be achieved.  Models of BSD have been published describing the effect of 
the addition of a binding agent to the dialysate stream on bound solute removal, the effect of 
convection (ultrafiltration) on bound solute removal, and the use of solid adsorbents to remove 
bound solutes.  The model presented here explores the reaction kinetics of BSD.  The kinetic 
model of BSD also provides a platform for the comparison of the original Patzer model of BSD 
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that makes the assumption of reaction equilibrium with a kinetic model that relaxes the 
equilibrium assumption, when it comes to BSD performance.   
The dimensionless parameters governing removal in the kinetic description of BSD are: 
the membrane mass transport/blood flow rate ratio, κ; the dialysate/blood flow rate ratio, α; the 
dialysate side/blood side volume ratio, γ; the dialysate/blood total albumin concentration ratio, β; 
the dissociation reaction rate/blood flow rate ratio, Da1; and the association reaction rate/blood 
flow rate ratio, Da2.  The first four parameters, κ, α, γ, and β, are either dialysis operating 
parameters or can be controlled to some degree by dialyzer choice.  Since the blood flow rate is 
chosen based on the clinical situation the Damkohler numbers for dissociation and association, 
Da1 and Da2 respectively, are determined by the solute-binder system being considered.  In the 
blood the main carrier of solutes that are of interest in liver failure is albumin, but the binder on 
the dialysate side could potentially be chosen based on the target solute.  Removal was found to 
be insensitive to changes in the dialysate/blood compartment volume ratio, γ, regardless of other 
parameters tested.  The equilibrium models presented by Patzer include a term describing the 
ratio of the binding constants on the blood and dialysate sides to account for a different binder in 
the blood and dialysate.  As the model is described here, the same binder is considered on both 
sides and there is only one binding reaction considered, so the values of Da1 and Da2 are the 
same for the blood side and the dialysate side.  The addition of different binders on the dialysate 
and blood sides would necessitate having different Da1 and Da2 values for the equations 
describing the blood and dialysate sides to reflect the binder-solute interaction on the respective 
sides with no additional mathematical complexity.  The addition of multiple binders or multiple 
solutes would add additional equations and terms in the equations describing the new 
interactions.  Multiple solutes interacting with the binding agent would add two ODEs on both 
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the blood and dialysate sides for each additional solute to describe the free and bound solute 
concentration on each side, but, assuming the solute-binder interaction is still a 1:1 reaction as 
described in the introduction, wouldn’t add additional terms to the equations.  Multiple binders 
with one solute would add one ODE on each side to describe the concentration profile of the 
solute complex with the second binder, and would add loss and generation by reaction terms to 
the equations describing the free concentration to describe the reactions with the second binder. 
Initial attempts to obtain a numerical solution to the system of nonlinear ODEs derived to 
describe the kinetic model of BSD were performed using the MATLAB ODE solvers used 
previously (ode45, ode15s, ode23, and ode23s).  The numerical solvers included ones that are 
meant for “stiff” and other difficult to solve system of ODEs.  Although the original Patzer 
model of BSD would solve using any of the older solvers, the normalized kinetic model would 
not.  When the dimensional kinetic model was used (as opposed to the normalized model) some 
cases would solve.  Since these solvers are for initial value problems (as opposed to boundary 
value problem solvers), additional steps need to be taken to pose the boundary conditions as 
initial values at one end and then match the output to the boundaries on the other side.  The 
boundary value problem solvers, bvp4c and bvp5c (included in MATLAB 6.0 and later), solved 
most cases of the kinetic model, and did so in considerably less time than the older ODE solvers.  
A description of the numerical methods used in this solver can be found at the MATLAB 
website, www.mathworks.com.  Both bvp4c and bvp5c are of forth order accuracy, and only 
differ in the method used for residual control.  Both bvp4c and bvp5c were used to solve several 
cases of the kinetic BSD model, and when no practical difference was found in the solution 
provided or the solution time needed, bvp4c was chosen arbitrarily for the rest of the simulations. 
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In all cases tested, the fractional removal found using the equilibrium model was the 
same as or higher than fractional removal found using the kinetic description.  This makes sense 
when one considers that a depletion effect on the blood side always exists as the concentration is 
reduced and time is needed for the dissociation of the solute-binder complex.  Conversely there 
will always be a higher free concentration in the dialysate than will be indicated by the 
equilibrium model since the association step always takes a finite time to occur.  The equilibrium 
model can therefore be taken as an upper bound for the removal rate.   
For lightly bound solutes (KB=100), no difference was seen between the removal found 
using either the equilibrium model or the kinetic model.  No improvement to removal rates were 
seen with the addition of binder to the dialysate stream, and no change in removal rates were 
seen with faster kinetics (higher Da1 and Da2).  For such lightly bound solutes, the assumption 
can be made that the total concentration (as opposed to the free or unbound concentration) is the 
driving force for solute removal and the removal rates can be assumed to follow descriptions for 
conventional aqueous dialysis. 
For moderately bound solutes (KB = 104, Da1/Da2 = 0.15) the situation arises that for low 
end dialysate flow rates and high end blood side flow rates, α-, with less binder than is required 
to approach maximum removal, the deviation increases with faster kinetics (lower removal), but 
for higher sweep fluid flow rates, α+, and high dialysate side albumin concentrations,β, the 
deviation decreases with faster kinetics (increased removal).  For α- with low β, faster kinetics 
will result in the blood side producing free solute at a higher rate, but the dialysate side carrying 
capacity (the amount of solute that can be carried out of the system by the dialysate, roughly 
proportional to the product QD(CA,total)D) is insufficient to keep up with the rate that solute 
transits the membrane.   
 68 
It is not possible based on these simulations to determine general trends for tightly bound 
solutes (KB=106) given that the simulations were unstable and would not solve at higher values of 
Da1 and Da2 or low values of β.  This apparent instability points out a situation where the 
original Patzer equilibrium model of BSD is the better model even when it is not as good a 
representation of the actual removal rates.  It will do no good to use a more complete (and 
complicated) model for the removal if it can’t be solved, even if the alternative over estimates 
the removal by almost 40%. 
5.4 CONCLUSION 
Hemodialysis, whether only hemodialysis (diffusive flux), hemofiltration (convective flux), or 
hemodiafiltration (both diffusion and convection), is performed with the therapeutic goal of 
removing a set of solutes that are present in the blood at higher concentrations than are desirable 
and the removal of bulk fluid.  In liver failure the solutes that build up in the patient’s blood tend 
to be albumin bound and sparingly soluble.  A typical hemodialysis membrane has a sieving 
coefficient of <1% for albumin, meaning that, whether by diffusion or by convection, <1% of the 
albumin present in the blood will transit the membrane, and the same is true for albumin bound 
solutes.  For a solute such as bilirubin where the majority is bound to albumin (or any large 
carrier) in the blood the removal is limited to the free fraction, and the free solute concentration 
is very low.  This small driving force for diffusion makes the removal of tightly bound solutes, 
whether to albumin or other carriers such as red blood cells, by dialysis to slow to provide an 
effective therapy.  Once a small amount of solute has passed into the dialysate stream the 
removal is further slowed by the reduction in the free solute concentration gradient across the 
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membrane, the driving force for the diffusion of bound solutes.  The addition of a binding agent, 
such as albumin, to the dialysate stream to bind solute as it transits the membrane is one 
proposed method to increase the rate of removal of tightly bound solutes by hemodialysis. 
For the simple 1:1 solute-binder interaction that is described here, the additional 
mathematical complexity and numerical stability problems with the kinetic description of BSD 
certainly reduces its potential utility.  While the equilibrium model overestimated removal by 
almost 40%, it provides a reasonable estimate of the removal potential based on the equilibrium 
binding constant.  The utility of the equilibrium model becomes more obvious when considering 
the lack of good information describing the kinetics of albumin solute interactions.  A more 
significant difference may be seen between the equilibrium and kinetic descriptions of BSD 
when additional binder-solute interactions (multiple binders with one solute, one binder and 
multiple solutes, or multiple binders with multiple solutes) are considered.   
 70 
6.0  SPECIFIC AIM 3:  EXAMINING THE PENETRATION OF ALBUMIN INTO 
COMMERCIAL DIALYSIS FIBERS 
While studies in our lab have shown different commercial dialysis membranes, of the same 
nominal surface area, to have different rates of removal of the tightly albumin bound solute 
bilirubin (data not published), the reason for the difference on removal rates is not clear why.  
Possible explanations for the differences in removal rates that are seen between commercial 
dialyzer types (after correcting for area) include dialysis membrane and solute charge effects, 
polarity of the solute and the membrane, the thickness of the membrane walls, and the tortuosity 
of the pore network to name a few.  Dialysis membranes are typically considered to be 
impermeable to large proteins, like albumin, but the ability of albumin to enter or bind to the 
surface of the dialysis membrane or the pore walls could, for better or worse, impact the removal 
of tightly albumin bound solutes.  The designers of the MARS artificial liver support system 
(ALSS) advocated the use of the MARSFlux dialysis membrane.  The claim was that the 
properties of this particular membrane, a polyethersulfone (PES) high flux dialysis membrane, 
allows albumin to penetrate into the membrane pores.  PES membranes typically have a fine 
pored inner lumen for sieving and an open fingerlike support layer.  Albumin penetration into the 
membrane could contribute to the removal of solutes by binding the solutes directly and by 
contributing additional transport mechanisms (surface diffusion, decreased diffusional distance, 
or decreased free solute concentration).  The relatively open pore structure of PES membranes 
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also expose more surface area for high molecular weight proteins to adsorb directly to the 
membrane surface.  The equivalent dialyzer produced by Gambro, who currently owns the 
MARS technology, has a similar pore structure as do other membranes produced by thermally 
induced phase separation.[67-69] 
The designers of the MARS prescribe a 1 hour cartridge pretreatment with a 10% 
albumin solution before it is used with a patient.[1]  Their claim is that this pretreatment 
impregnates the membrane with albumin.  When a solution containing high concentrations of 
protein is run across a filter (especially in the case of perpendicular or dead end ultrafiltration) a 
polarization layer develops close to the membrane, and generally a protein cake or gel layer 
forms on the membrane surface.[55]  Although the cross flow configuration of a dialysis 
cartridge minimizes the gel layer formation, several studies have shown a significant amount of 
albumin and other proteins will penetrate into conventional dialysis membranes during clinical 
use.[67, 70]  Clark et. al. investigated the adsorption of the small protein β2-microglobulin and of 
bovine serum albumin to the surface of polyacrylonitrile (PAN) and cellulose triacetate (CT) 
dialysis membranes.  Polyacrylonitrile and cellulose triacetate dialysis membranes were 
incubated in solutions containing radiolabeled β2-microglobulin or bovine serum albumin.  
Significantly more β2-microglobulin adsorbed to the surface than albumin.  The higher β2-
microglobulin adsorption was taken by the authors as indication of β2-microglobulin adsorption 
to the inner surface of the pores but the exclusion of the larger albumin molecule from the pore 
network.[71]  Fujimori et. al. measured the adsorption of several proteins, including albumin, to 
CT, polymethylmethacrylate (PMMA), and PAN clinical dialyzer membranes.  After use in the 
renal dialysis clinic, the dialysis membranes were washed with saline and fixed using 2% 
paraformaldehyde.  The proteins were then labeled using fluorescently tagged antibodies.  The 
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fluorescence of the labeled proteins was measured using confocal laser microscopy.  A 
qualitative assessment of the albumin concentration showed adsorption to the outer surfaces of 
the CTA membrane, little adsorption to the PMMA, and albumin adsorption to the inner and 
outer surfaces as well as the pore network of the PAN membrane.[72] 
Early experiments by Patzer on the removal of bilirubin during albumin dialysis using a 
Cobe Centrysystem 300 HG dialyzer (second GmbH, Dransfeld, Germany) show what could be 
a shift to a higher order removal rate after about 180 min of contact time with 40 g L-1 BSA in 
PBS on the patient side and >4 g L-1 BSA in PBS on the dialysate side (Figure 6.1).[18]  This 
phenomena was never explained, but we have speculated that it may have to do with an adsorbed 
albumin layer building up and reaching a critical concentration where additional transport 
mechanisms may begin to contribute to removal.   
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Figure 6.1.  In vitro patients consisting of BSA (40 g L-1) in PBS spiked with unconjugated bilirubin were 
dialyzed against PBS (E1-E5) or PBS containing BSA (E6-E15) using pediatric cellulose acetate membranes. 
Removal for experiments using albumin containing dialysate all had essentially the same removal rate 
regardless of dialysate albumin concentration.  The removal rate of bilirubin shows a distinctly different 
removal rate after 180 minutes of contact time.  The change to a different removal rate was never explained, 
but the change in removal rate may be due to albumin penetrating the membrane and contributing additional 
removal mechanisms.  
 
The ability of albumin to bind to and enter the dialysis membrane may be one of the 
factors determining the rate of removal during an albumin dialysis procedure, and may be an 
important consideration in the choice of a dialyzer for use in albumin dialysis therapies.  The 
goal of this work is to improve our understanding of the mechanism of removal during albumin 
dialysis by developing small scale hollow fiber dialyzers using commercial dialysis fibers to 
allow for the direct imaging of protein penetration into the fiber in real time.  Small dialyzers 
designed for use in a microscopy facility also have potential as a platform for the examination of 
the Fahraeus-Lindquist effect (change in fluid viscosity with changes in capillary diameter as a 
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result of near wall cell free layer formation) in dialysis membranes and platelet margination in 
capillaries. 
6.1 MATERIALS AND METHODS 
Alexa 488 labeled BSA used was from Invitrogen (Carlsbad, CA).  Dialysis fibers were excised 
from Exeltra cellulose triacetate (Baxter Healthcare Corporation, Deerfield, IL), Multiflow 60 
AN69 (HOSPAL Industrie, Meyzieu, France), and Polyflux 11S polyarylethersulfone (Gambro 
Dialysatoren GmbH & Co. KG, Hechingen, Germany) commercial dialyzers (Figure 6.2 and 
Figure 6.3). 
 
 
Figure 6.2.  The commercial dialyzers used in our lab include (from left to right) Multiflow 60 AN69*, the 
pediatric Cobe Centrysystem 300 HG, the Gambro 500 HG hemophane, the Polyflux 11S 
polyarylethersulfone*, and the Exeltra cellulose triacetate dialyzers*.  Dialyzer used in this experimentation 
are marked with *. 
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Figure 6.3.  A high speed rotary tool was used to cut the shell off of the dialyzer to expose the membranes.  
The rotary tool was set to a high speed to melt the polycarbonate as it was cut to reduce the amount of dust 
generated. 
   
Plastic shim stock (PETG, 0.03” thickness) (McMaster-Carr, Robbinsville, NJ) was cut to 
fit on the microscope stage (80x100 mm) and a 15 mm hole was cut to accommodate the 
microscope objective.  A 45x50 mm coverslip (1.5 thickness) (Fisher Scientific, was affixed over 
the hole using general purpose (thick, non-flowable) silicone sealant (RTV sealant, 732 Multi-
Purpose Sealant, Dow Corning Corporation, Midland, MI).  Ten fibers were evenly spaced 
across the cover slip, and were affixed to the cover slip using general purpose silicone sealant.  
The fibers were gently pressed into the silicone so that they were in contact with the cover slip.  
Two lengths of microbore tygon tubing (2” length, 0.040” ID, 0.070” OD) (Saint-Gobain, 
Granville, NY), were positioned at the edge of the cover slip perpendicular to the fibers to create 
a cross flow configuration through the extracapillary space of the slide.  A 50x50 mm (~0.03” 
thickness) borosilicate slide glass (Eastman Kodak Company, Rochester, NY) was placed on top 
of the slide to create a flow chamber around the fibers, and the glass was sealed in place using 
general purpose silicone sealant.  The portion of the fibers outside of the glass chamber was then 
wetted with general purpose silicone sealant, gently gathered together, and allowed to dry 
overnight.  A 4 cm piece of silicone tubing (0.125” ID, 0.188” OD) (Cole-Parmer, Vernon Hills, 
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IL) was slid over the fibers on both sides of the slide dialyzer, and the tubing was backfilled with 
flowable silicone sealant (RTV sealant, 734 Multi-Purpose Sealant, Dow Corning Corporation, 
Midland, MI) to encase the fibers.  A razor blade was used to cut the tubing housing the fibers, 
opening the fibers to flow.  A female to female luer lock connector (Value Plastics, Fort Collins, 
CO) with one side bored out to the OD of the tubing used to house the fibers was glued in place 
with flowable RTV silicone sealant.  The area around the fibers and the edge of the slide glass 
was covered with flowable silicone to seal any leaks and gaps.  After allowing the silicone to 
fully cure, the slides were connected to a syringe pump at a flow rate of 1.0 ml min-1 to test for 
leaks.  A more complete procedure and diagrams are provided in Appendix D. 
 
6.2 RESULTS 
6.2.1 Slide dialyzer prototypes 
Nine slide prototypes (four with AN69 membranes, four with Exeltra CTA membranes, and one 
with 100 kDa CTA albumin permeable membranes (expired research bioreactor hollow fiber 
cartridge provided by Excorp Medical) were created.  During flow testing at 1 ml min-1, 
prototype 1 (AN69-1, Figure 6.4) had several leaks around the sides of the slide glass and where 
the fiber bundle enters the luer fittings.  After sealing the leaks with silicone grease (High 
vacuum grease, Dow Corning Corporation, Midland, MI) the slide maintained flow for 1hr 
without leaking, but was not used on a microscope owing to the risk of leaking.  For the second 
generation device (prototype 2, AN69-2, Figure 6.5), the diameter of the shell space tubing was 
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reduced (from 0.063” ID, 0.125” OD to 0.040” ID, 0.070 OD) and flowable RTV sealant was 
used to seal the area around the slide and where the fiber bundle enters the luer fittings.  The 
device was flow tested at 1 ml min-1 (fibers and shell in series) for approximately 5 minutes 
before the bottom cover slip burst (Figure 6.6).   
The rest of the prototypes were already under construction when prototype 2 failed, and 
no changes were made in the design of prototypes 3-9 (Figure 6.7).  Prototype 3 and prototype 4 
were both flow tested for 1 hr at 1 ml/min flow rate (fibers and shell in series).  Prototypes 5 
through 8 were not flow tested, and prototype 9 was not completed. 
 
 
Figure 6.4.  Prototype 1 (AN69-1) was the first attempt to create a slide dialyzer using fibers excised from a 
commercial dialyzer.  The slide dialyzer was made using membranes from an AN69 commercial dialyzer.  
Flow testing was performed using a syringe pump at 0.25 ml min-1.  Leaks were found at several points 
around the slide and at the luer fitting encasing the fibers.  Silicone grease was used to seal leaks, allowing the 
slide to hold a sustained flow of 1 ml min-1 for one hour during flow testing. 
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Figure 6.5.  Prototype 2 (AN69-2) was the second prototype produced.  Changes in the second generation 
prototype were smaller tubing for the extracapillary space and flowable RTV silicone sealant used to seal the 
space around the slide glass and the luer fitting with the fiber bundle.  The notches in the plastic support are 
to accommodate the shape of the stage on the Leica confocal microscope used.  Flow testing at 0.25 ml min-1 
produced enough pressure in the shell space to burst the coverslip. 
 
 
Figure 6.6.  Prototype 2 (AN69-2) shown here from underneath.  Once hooked up to a syringe pump at 0.25 
ml min-1 pressure build up in the extra capillary space burst the coverslip.   
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Figure 6.7.  Prototype slide dialyzers.  a: prototype 3 (AN69-3), b: prototype 4 (Exeltra-1), c: prototype 5 
(AN69-4), d: prototype 6 (Exeltra-2), e: prototype 7 (Excorp-1), f: prototype 8 (Exeltra-3), and g: prototype 9 
(Exeltra 4). 
 
6.2.2 Fiber auto-fluorescence and fluorophore choice 
Three fiber types were tested during these experiments, AN69, polysulfone (PS), and cellulose-
triacetate (CTA).  Dialysis membranes made from AN69 and cellulose triacetate are transparent, 
and the polysulfone membranes are opaque.  The AN69 and polysulfone fibers tested in these 
experiments exhibit broad range autofluorescence, absorbing and emitting over the range of 
commonly used fluorescent tags (Figure 6.8 and Figure 6.9).  Although the PS fibers tested are 
opaque, attempts were made to use 2-photon microscopy to image the fibers.  Only the outer skin 
and proximate interior of the larger pores of the PS membrane could be seen.  The inside of the 
PS fiber wall and the inner surface of the fiber could not be imaged.   
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Figure 6.8.  AN69 polyacylonitrile dialysis membranes exhibit broad range auto fluorescence.  The fiber is 
shown here under bright field (top left), Cy3 channel (550 nm excitation, 570 nm emission), FITC channel 
(495 nm excitation, 520 nm emission), and unfiltered mercury vapor lamp UV excitation and unfiltered 
autofluoresence. 
  
 
Figure 6.9.  Polyethersulphone membranes (outer diameter=265 μm) are opaque, but have broad range 
autofluorescence over a broad range of excitation wavelengths.  The membrane is shown here in its 
autofluorescence (excitation=488 nm, emission=520 nm) showing the pores at the surface (left) and at half 
depth (right). 
 
Prototype 3 (AN69-3) was imaged on a Leica DMI 4000 B confocal microscope (Leica 
Microsystems Inc., Buffalo Grove, IL).  Despite best efforts during fabrication to have the entire 
fiber length lie flat on the cover slip surface, all but one of the fibers were too far from the cover 
slip to image.  A syringe was used to fill both the fiber lumen and the shell space with PBS, and 
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a cross section of the dialysis fiber at half depth was imaged (Figure 6.10).  Without 
repositioning the slide, the fiber lumen was then filled with Alexa 488 labeled BSA.  The fiber 
was again imaged at half depth.  The labeled BSA can be clearly seen in the fiber lumen.  No 
fluorescent signal was seen in the shell space indicating that there were no leaks from the fiber 
lumen flow path to the shell space of the slide dialyzer.   
 
  
Figure 6.10.  AN69-3 slide cartridge with polyacylonitrile dialysis membranes is shown here at half depth in 
its autofluorescence (excitation=488 nm, emission=520 nm) filled with PBS (left). A syringe was used to fill the 
lumen of the fiber with Alexa 488 labeled bovine albumin (Invitogen, Carlsbad, CA).  
6.3 DISSCUSION AND CONCLUSIONS 
The choice of an appropriate dialyzer for use in an albumin dialysis system could have a 
significant impact on its removal effectiveness.  Although we know from experimentation done 
in our lab that significant differences exist in the removal capability of commercial dialyzers of 
the same nominal surface area when they are used for albumin dialysis, the reason for the 
difference is not clear.  Slide dialyzers like those presented here have the potential to provide a 
platform to study some of the differences between optically transparent dialysis membranes, and 
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have the potential to provide real time concentration profiles of compounds passing through the 
dialysis membrane. 
Although I was able to provide proof of concept, no information on the albumin 
penetration into the dialysis membranes was elucidated through this project.  The slide dialyzers 
presented are a viable design, but the design has several flaws.  The risk of breaking the cover 
slip from the pressure required to drive flow through the extra-capillary space was seen with the 
second device made.  The cover slip breakage can be addressed in several ways.  A slower flow 
rate will reduce the pressure in the extra-capillary space. The use of larger tubing for the extra-
capillary space will reduce the pressure, but would increase the volume of the extra-capillary 
space.  A thicker cover slip could be used, but that would require the use of longer working-
distance microscope objectives than were available on the microscope used.  In the tests done on 
the slide dialyzers the flow was driven using a syringe pump.  Driving the extra-capillary space 
flow using suction will also mitigate the leakage that would be caused in the case of a break by 
stopping the flow as soon as suction is lost. 
The auto-fluorescence that is seen with the dialysis fibers tested interferes with the signal 
that would be seen from the labeled albumin as it enters the fiber wall.  In order to make accurate 
measurements of the concentration of the labeled protein, the noise from the fiber 
autofluorescence signal needs to be minimized.  The fiber autofluorescence needs to be mapped 
to find an excitation/emission that minimally interferes with available fluorescent tags.  This can 
be done by scanning the autofluorescence emission at the available laser wavelengths and 
choosing a fluorescent tag that will fall into a region of low background. 
The use of small scale slide dialyzers has the potential to provide a method by which the 
interaction between commercial dialysis membranes and proteins during use without the need for 
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fixing the proteins and sectioning the fibers after use.  In addition to the intended use of 
examining the penetration of albumin into the fiber wall, a slide dialyzer like those presented 
here could be used to examine the cell free layer formation that occurs in commercial dialysis 
fiber, platelet margenation in blood flow, and the interaction between the dialysis membrane 
with any type of cells in flow (red blood cells, leukocytes, or platelets). 
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APPENDIX A                                                                                                                          
SYMBOL DEFINITIONS 
Symbol     
 
Units 
 
Definition 
L  Liter  Volume in liters 
mol  mole  Mass in moles 
s  second  Time in seconds 
g  gram  Mass in grams 
dL  deciliter   Volume in deciliters (1 dL = 0.1 L) 
m  meter  Length in meters 
m2  square meter  Area in square meters 
°C  degree Celsius  Temperature in degrees Celsius 
K  Kelvin  Temperature in Kelvin 
J  Joule  Energy in Joules 
nm  nanometer  Length in nanometers 
RU  relative response units  Dimensionless relative response units 
μg  microgram  Mass in microgram 
mmol  millimole  Mass in millimoles 
mL  milliliter  Volume in milliliters 
μmol  micromole  Mass in micromoles 
min  minutes  Time in minutes 
mm  millimeters  Length in millimeters 
"  inch  Length in inches 
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APPENDIX B                                                                                                                            
SPECIFIC AIM 1 
B.1 Derivation of SPR curve fitting equations 
The reaction at the surface of a sensor chip can be described as a reaction between a solute that is 
free in solution (A) and a reacting site on a molecule that has been bound to the surface (B) to 
form the complex AB (Figure B.1).   
 
 
Figure B.1.  Reactant B is bound to the sensor chip surface to form reacting sites, [CB]t (top).  If all of the 
available sites are occupied, the complex concentration reaches its theoretical maximum, [CAB]max (middle).  
The concentrations of occupied and free sites are CAB and CB, respectively (bottom). 
 
Biacore SPR tracks the rate of formation of the AB complex at the sensor chip surface.  The 
formation of the complex proceeds according to the 1:1 reaction 
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a
d
k
k
A B AB+ 
           
Equation B.1 
 
Where ka and kd are the reaction rates of association and dissociation respectively.  In the case 
that there is more than one type of binding site on the surface, the reactions are considered to be 
independent and the SPR response is additive.  The rate of formation of the complex at the chip 
surface is  
 
AB
a A B d AB
dC k C C k C
dt
= −
          
Equation B.2
 
 
Where t is time and the Ci are the solute solution concentration, the concentration of free sites, 
and the concentration of the complex (subscripts A, B, and AB respectively).  If the maximum 
concentration of the complex is [CAB]max, then the number of free sites, CB, is 
 
max[ ]B AB ABC C C= −          Equation B.3 
 
The mass balance (Equation B.3) can be substituted into Equation B.2 
 
max([ ] )AB a A AB AB d AB
dC k C C C k C
dt
= − −
      
Equation B.4
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The SPR response is considered to be proportional to the concentration of the complex at the 
sensor chip surface, and that proportionality is constant with changes in the complex 
concentration. 
 
max max[ ]AB ABR aC R a C= → =         Equation B.5 
 
where R is the SPR response, a is an arbitrary proportionality constant, and Rmax is the theoretical 
maximum signal that is obtained is all of the sites on the surface are occupied.  Using the relation 
in Equation B.5, Equation B.4 can now be put in terms of SPR response. 
 
max
max
( ) ( )
( )
a A d
a A d
d aR k C aR aR k aR
dt
dR k C R R k R
dt
= − −
↓
= − −
       Equation B.6 
 
Equilibrium response analysis (determining KB):  When the reaction at the sensor chip’s surface 
is at equilibrium, the rate of change of the SPR signal is zero. 
 
max0 ( )a A d
dR k C R R k R
dt
= = − −         Equation B.7 
 
The equilibrium binding constant (KB) is the ratio of the rate of association (ka) to the rate of 
dissociation (kd) of the AB complex (Equation 4.2).  Equation B.7 can now be put in terms of the 
equilibrium binding constant instead of the reaction rate constants by dividing through by kd. 
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max
max
0
0
a a
A A
d d
B A B A
k kC R C R R
k k
K C R K C R R
= − −
↓
= − −
        Equation B.8 
 
The right hand side of Equation B.8 can now be solved for the equilibrium response value, R. 
 
max
1
B A
B A
K C RR
K C
=
+          
Equation B.9
 
 
The scrubber software package fits Equation B.9 to the equilibrium SPR response data using a 
nonlinear least squares fitting method with KB and Rmax as the adjustable parameters.  For a given 
solute-binder pair, Equation B.9 is globally fit to all of the data sets simultaneously 
Transient response analysis (determining ka and kd):  To determine the reaction rate constants 
during the association phase of the experiment, Equation B.6 can be integrated and the transient 
response can be fit to the integrated equation. 
max
max
0
( )
( )
, . : 0
a A d
a A a A d
a b
t
dR k C R R k R
dt
dR k C R R k C k
dt
dR dt i c R
a bR =
= − −
↓
= + − −
↓
= =
+∫ ∫
 
       Equation B.10 
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Integrating Equation B.10 with its initial conditions yields the equation for the response during 
the association phase as a function of time. 
 
( )max (1 )a A dk C k ta A
a A d
k C RR e
k C k
− += −
+
        Equation B.11 
 
Equation B.11 is fit to the association phase of the SPR response data by the Scrubber software 
package using a nonlinear least squares fitting method with ka, kd, and Rmax as the adjustable 
parameters.  For a given solute-binder pair, Equation B.11 is globally fit to all of the data sets 
simultaneously. 
 During the dissociation phase of the experiment ka =0, making the rate of change of the 
SPR response curve 
 
d
dR k R
dt
= −           Equation B.12 
 
To determine the reaction rate constants during the dissociation phase of the experiment, 
Equation B.12 can be integrated and the transient response can be fit to the integrated rate 
equation. 
 
0
0, . .d t t
dR k dt i c R R
R =
= − =∫ ∫         Equation B.13 
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where R0 is the SPR response at t0, which is the beginning of the dissociation phase.  Integrating 
Equation B.13 with its initial condition yields the equation for the response during the 
dissociation phase as a function of time. 
 
0( )
0
dk t tR R e− −=           Equation B.14 
B.2 SPR response curves with curve fits 
 
Figure B.2.  SPR response (jagged curves) for bilirubin binding to BSA at 22oC (left) with rate equation curve 
fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods built into 
SCRUBBER-2.  The association (ka = 1.010(6)x105 L mole-1 s-1) and dissociation (kd = 0.175(2) s-1) rates and 
maximal response (Rmax = 52.21(6)) were the adjustable parameters in the fit.  The residuals (residual=(data 
value)-(model fit value)) of the curve fit are shown at right.  The SPR curves used for determining kinetic rate 
constants have the high concentration curves removed to restrict the binding reaction to the higher affinity 
binding site.  Numbers in parentheses denote the error associated with the last significant digit. 
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Figure B.3.  SPR response (jagged curves) for bilirubin binding to BSA at 37oC (left) with rate equation curve 
fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods built into 
SCRUBBER-2.  The association (ka = 1.70(2)x105 L mol-1 s-1) and dissociation (kd = 0.535(8) s-1) rates and 
maximal response (Rmax = 33.81(8)) were the adjustable parameters in the fit.  The residuals (residual=(data 
value)-(model fit value)) of the curve fit are shown at right.  The SPR curves used for determining kinetic rate 
constants have the high concentration curves removed to restrict the binding reaction to the higher affinity 
binding site. Numbers in parentheses denote the error associated with the last significant digit. 
 
 
Figure B.4.  SPR response (jagged curves) for bilirubin binding to HSA at 22oC (left) with rate equation curve 
fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods built into 
SCRUBBER-2.  The association (ka = 6.55(5)x104 L mole-1 s-1) and dissociation (kd = 0.0282(3) s-1) rates and 
maximal response (Rmax = 118.3(3)) were the adjustable parameters in the fit.  The residuals (residual=(data 
value)-(model fit value)) of the curve fit are shown at right.  The SPR curves used for determining kinetic rate 
constants have the high concentration curves removed to restrict the binding reaction to the higher affinity 
binding site. Numbers in parentheses denote the error associated with the last significant digit. 
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Figure B.5.  SPR response (jagged curves) for bilirubin binding to HSA at 37oC (left) with rate equation curve 
fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods built into 
SCRUBBER-2.  The association (ka = 1.60(4)x105 L mol-1 s-1) and dissociation (kd = 0.128(3) s-1) rates and 
maximal response (Rmax = 59.6(5)) were the adjustable parameters in the fit.  The residuals (residual=(data 
value)-(model fit value)) of the curve fit are shown at right.  The SPR curves used for determining kinetic rate 
constants have the high concentration curves removed to restrict the binding reaction to the higher affinity 
binding site. Numbers in parentheses denote the error associated with the last significant digit. 
 
 
Figure B.6.  SPR response (jagged curves) for FK506 binding to BSA at 22oC (left) with rate equation curve 
fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods built into 
SCRUBBER-2.  The association (ka = 94.4(6) L mol-1 s-1) and dissociation (kd = 0.0100(1) s-1) rates and 
maximal response (Rmax = 99(1)) were the adjustable parameters in the fit.  The residuals (residual=(data 
value)-(model fit value)) of the curve fit are shown at right.  The SPR curves used for determining kinetic rate 
constants have the high concentration curves removed to restrict the binding reaction to the higher affinity 
binding site. Numbers in parentheses denote the error associated with the last significant digit. 
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Figure B.7.  SPR response (jagged curves) for FK506 binding to BSA at 37oC (left) with rate equation curve 
fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods built into 
SCRUBBER-2.  The association (ka = 9.3(2)x103).1 L mol-1 s-1) and dissociation (kd = 0.81(1) s-1) rates and 
maximal response (Rmax = 172.3(4)) were the adjustable parameters in the fit.  The residuals (residual=(data 
value)-(model fit value)) of the curve fit are shown at right.  The SPR curves used for determining kinetic rate 
constants have the high concentration curves removed to restrict the binding reaction to the higher affinity 
binding site. Numbers in parentheses denote the error associated with the last significant digit. 
 
 
Figure B.8.  The SPR response for FK506 binding to HSA at 22oC could not be used for curve fitting with the 
rate equations (Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods built into 
SCRUBBER-2.  The fit tolerances could not be met by the software solvers. 
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Figure B.9.  SPR response (jagged curves) for FK506 binding to HSA at 37oC (left) with rate equation curve 
fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods built into 
SCRUBBER-2.  The association (ka = 6.0(5)x103 L mol-1 s-1) and dissociation (kd = 0.60(1) s-1) rates and 
maximal response (Rmax = 108.2(3)) were the adjustable parameters in the fit.  The residuals (residual=(data 
value)-(model fit value)) of the curve fit are shown at right.  The SPR curves used for determining kinetic rate 
constants have the high concentration curves removed to restrict the binding reaction to the higher affinity 
binding site. Numbers in parentheses denote the error associated with the last significant digit. 
 
 
Figure B.10.  SPR response (jagged curves) for cholic acid binding to BSA at 22oC (left) with rate equation 
curve fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods built into 
SCRUBBER-2.  The association (ka = 1.09(3)x105 L mol-1 s-1) and dissociation (kd = 2.33(6) s-1) rates and 
maximal response (Rmax = 68.5(1)) were the adjustable parameters in the fit.  The residuals (residual=(data 
value)-(model fit value)) of the curve fit are shown at right.  The SPR curves used for determining kinetic rate 
constants have the high concentration curves removed to restrict the binding reaction to the higher affinity 
binding site. Numbers in parentheses denote the error associated with the last significant digit. 
 95 
 
Figure B.11.  SPR response (jagged curves) for cholic acid binding to BSA at 37oC (left) with rate equation 
curve fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods built into 
SCRUBBER-2.  The association (ka = 1.10(4)x105 L mol-1 s-1) and dissociation (kd = 3.2(1) s-1) rates and 
maximal response (Rmax = 69.4(1)) were the adjustable parameters in the fit.  The residuals (residual=(data 
value)-(model fit value)) of the curve fit are shown at right.  The SPR curves used for determining kinetic rate 
constants have the high concentration curves removed to restrict the binding reaction to the higher affinity 
binding site. Numbers in parentheses denote the error associated with the last significant digit. 
 
 
Figure B.12.  SPR response (jagged curves) for cholic acid binding to HSA at 22oC (left) with rate equation 
curve fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods built into 
SCRUBBER-2.  The association (ka = 7.2(3)x104 L mol-1 s-1) and dissociation (kd = 4.5(2) s-1) rates and 
maximal response (Rmax = 47.70(9)) were the adjustable parameters in the fit.  The residuals (residual=(data 
value)-(model fit value)) of the curve fit are shown at right.  The SPR curves used for determining kinetic rate 
constants have the high concentration curves removed to restrict the binding reaction to the higher affinity 
binding site. Numbers in parentheses denote the error associated with the last significant digit. 
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Figure B.13.  SPR response (jagged curves) for cholic acid binding to HSA at 37oC (left) with rate equation 
curve fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods built into 
SCRUBBER-2.  The association (ka = 8.7(7)x104 L mol-1 s-1) and dissociation (kd = 6.4(5) s-1) rates and 
maximal response (Rmax = 35.6(1)) were the adjustable parameters in the fit.  The residuals (residual=(data 
value)-(model fit value)) of the curve fit are shown at right.  The SPR curves used for determining kinetic rate 
constants have the high concentration curves removed to restrict the binding reaction to the higher affinity 
binding site. Numbers in parentheses denote the error associated with the last significant digit. 
 
 
Figure B.14.  SPR response (jagged curves) for deoxycholic acid binding to BSA at 22oC (left) with rate 
equation curve fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods 
built into SCRUBBER-2.  The association (ka = 1.35(1)x105 L mol-1 s-1) and dissociation (kd = 0.845(8) s-1) rates 
and maximal response (Rmax = 82.57(8)) were the adjustable parameters in the fit.  The residuals 
(residual=(data value)-(model fit value)) of the curve fit are shown at right.  The SPR curves used for 
determining kinetic rate constants have the high concentration curves removed to restrict the binding 
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reaction to the higher affinity binding site. Numbers in parentheses denote the error associated with the last 
significant digit. 
 
 
Figure B.15.  SPR response (jagged curves) for deoxycholic acid binding to BSA at 37oC (left) with rate 
equation curve fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods 
built into SCRUBBER-2.  The association (ka = 1.41(1)x105 L mol-1 s-1) and dissociation (kd = 1.35(1) s-1) rates 
and maximal response (Rmax = 90.25(7)) were the adjustable parameters in the fit.  The residuals 
(residual=(data value)-(model fit value)) of the curve fit are shown at right.  The SPR curves used for 
determining kinetic rate constants have the high concentration curves removed to restrict the binding 
reaction to the higher affinity binding site. Numbers in parentheses denote the error associated with the last 
significant digit. 
 
 
Figure B.16.  SPR response (jagged curves) for deoxycholic acid binding to HSA at 22oC (left) with rate 
equation curve fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods 
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built into SCRUBBER-2.  The association (ka = 1.62(3)x105 L mol-1 s-1) and dissociation (kd = 2.09(4) s-1) rates 
and maximal response (Rmax = 65.74(9)) were the adjustable parameters in the fit.  The residuals 
(residual=(data value)-(model fit value)) of the curve fit are shown at right.  The SPR curves used for 
determining kinetic rate constants have the high concentration curves removed to restrict the binding 
reaction to the higher affinity binding site. Numbers in parentheses denote the error associated with the last 
significant digit. 
 
 
Figure B.17.  SPR response (jagged curves) for deoxycholic acid binding to HSA at 37oC (left) with rate 
equation curve fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods 
built into SCRUBBER-2.  The association (ka = 2.13(7)x105 L mol-1 s-1) and dissociation (kd = 6.1(2) s-1) rates 
and maximal response (Rmax = 74.2(1)) were the adjustable parameters in the fit.  The residuals 
(residual=(data value)-(model fit value)) of the curve fit are shown at right.  The SPR curves used for 
determining kinetic rate constants have the high concentration curves removed to restrict the binding 
reaction to the higher affinity binding site. Numbers in parentheses denote the error associated with the last 
significant digit. 
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Figure B.18.  SPR response (jagged curves) for glycocholic acid binding to BSA at 22oC (left) with rate 
equation curve fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods 
built into SCRUBBER-2.  The association (ka = 4.4(2)x104 L mol-1 s-1) and dissociation (kd = 1.77(6) s-1) rates 
and maximal response (Rmax = 58.5(2)) were the adjustable parameters in the fit.  The residuals 
(residual=(data value)-(model fit value)) of the curve fit are shown at right.  The SPR curves used for 
determining kinetic rate constants have the high concentration curves removed to restrict the binding 
reaction to the higher affinity binding site. Numbers in parentheses denote the error associated with the last 
significant digit. 
 
 
Figure B.19.  SPR response (jagged curves) for glychoic acid binding to BSA at 37oC (left) with rate equation 
curve fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods built into 
SCRUBBER-2.  The association (ka = 4(2)x103 L mol-1 s-1) and dissociation (kd = 2.4(1) s-1) rates and maximal 
response (Rmax = 438(2)) were the adjustable parameters in the fit.  The residuals (residual=(data value)-
(model fit value)) of the curve fit are shown at right.  The SPR curves used for determining kinetic rate 
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constants have the high concentration curves removed to restrict the binding reaction to the higher affinity 
binding site. Numbers in parentheses denote the error associated with the last significant digit. 
 
 
Figure B.20.  SPR response (jagged curves) for glycocholic acid binding to HSA at 22oC (left) with rate 
equation curve fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods 
built into SCRUBBER-2.  The association (ka = 6.1(5)x104 L mol-1 s-1) and dissociation (kd = 3.7(3) s-1) rates 
and maximal response (Rmax = 25.45(9)) were the adjustable parameters in the fit.  The residuals 
(residual=(data value)-(model fit value)) of the curve fit are shown at right.  The SPR curves used for 
determining kinetic rate constants have the high concentration curves removed to restrict the binding 
reaction to the higher affinity binding site. Numbers in parentheses denote the error associated with the last 
significant digit. 
 
 
Figure B.21.  SPR response (jagged curves) for glycocholic acid binding to HSA at 37oC (left) with rate 
equation curve fits (smooth lines, Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods 
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built into SCRUBBER-2.  The association (ka = 1.1(8)x104 L mol-1 s-1) and dissociation (kd = 13(2) s-1) rates 
and maximal response (Rmax = 213(1)) were the adjustable parameters in the fit.  The residuals 
(residual=(data value)-(model fit value)) of the curve fit are shown at right.  The SPR curves used for 
determining kinetic rate constants have the high concentration curves removed to restrict the binding 
reaction to the higher affinity binding site. Numbers in parentheses denote the error associated with the last 
significant digit. 
 
 
Figure B.22.  The SPR response for cyclosporin A binding to BSA at 22oC could not be used for curve fitting 
with the rate equations (Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods built into 
SCRUBBER-2.  The fit tolerances could not be met by the software solvers. 
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Figure B.23.  The SPR response for cyclosporin A binding to BSA at 37oC could not be used for curve fitting 
with the rate equations (Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods built into 
SCRUBBER-2.  The unusually high response for the size of the cyclosporine A molecule is indicative of 
aggregates of the solute binding with the surface. 
 
 
Figure B.24.  The SPR response for cyclosporin A binding to HSA at 22oC could not be used for curve fitting 
with the rate equations (Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods built into 
SCRUBBER-2.  The fit tolerances could not be met by the software solvers. 
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Figure B.25.  The SPR response for cyclosporin A binding to BSA at 37oC could not be used for curve fitting 
with the rate equations (Equation 4.5 and Equation 4.6) using the non-linear curve fitting methods built into 
SCRUBBER-2.  The unusually high response for the size of the cyclosporine A molecule is indicative of 
aggregates of the solute binding with the surface. 
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B.3 Binding constant detailed results 
Table B.1.  BSA/small molecule equilibrium dissociation constants (KD, mol L-1) obtained by fitting the 
equilibrium portion of SPR response curves for a binding pair at a given temperature to Equation 4.5.  KD1, 
KD2, and the Rmax values (KD1 and KD2 have separate Rmax values associated with them) were the adjustable 
parameters in the curve fits.  The number in the parentheses is the error associated with the last digit.  For 
example for bilirubin at 22°C KD1=970x10-9 ± 20x10-9. 
 
 
KD1 % error Rmax  KD2 % error Rmax 
Bilirubin 22°C 970(20) nM 2.1 89.8(7) 
 ---- ---- ---- 
37°C 1.19(4) μM 3.4 55.0(6)  ---- ---- ---- 
  
   
 
   
FK506 22°C 960(70) μM 7.3 
200  ---- ---- ---- 
37°C 75.2(7) uM 0.9 200  ---- ---- ---- 
  
   
 
   
Colic acid 22°C 11.4(3) uM 0.7 32.1(6) 
 168(3) uM 1.8 117.3(3) 
37°C 19.1(3) uM 1.6 44.6(7)  370(20) uM 5.4 102(1) 
  
   
 
   Deoxycholic 
acid 
22°C 6.9(1) uM 1.4 79.0(9)  330(10) uM 3.0 259(3) 
37°C 7.4(1) uM 1.4 67.8(8)  320(10) uM 3.1 242(3) 
    
 
 
   Glycocholic 
acid 
22°C 41(4) uM 9.8 39(6)  350(50) uM 14.3 123.19 
37°C 60(5) uM 8.3 40(3)  620(60) uM 9.7 123.19 
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Table B.2.  HSA/small molecule equilibrium dissociation constants (KD, mol L-1) obtained by fitting the 
equilibrium portion of SPR response curves for a binding pair at a given temperature to Equation 4.5.  KD1, 
KD2, and the Rmax values (KD1 and KD2 have separate Rmax values associated with them) were the adjustable 
parameters in the curve fits.  The number in the parentheses is the error associated with the last digit.  For 
example for bilirubin at 22°C KD1=1.00x10-6 ± 0.02x10-6. 
 
 
KD1 % error Rmax  KD2 % error Rmax 
Bilirubin 22°C 1.00(2) uM 2.0 144.4(8) 
 ---- ---- ---- 
37°C 2.08(6) uM 2.9 80.4(8)  ---- ---- ---- 
     
 
  
 
FK506 22°C 730(20) uM 2.7 200 
 ---- ---- ---- 
37°C 158(1) uM 0.6 200  ---- ---- ---- 
     
 
  
 
Colic acid 22°C 42(2) uM 4.8 17(2) 
 280(20) uM 7.1 92.32 
37°C 64.2(9) uM 1.4 17  503(2) uM 0.4 92.32 
     
 
  
 
Deoxycholic 
acid 
22°C 11.6(1) uM 0.9 54.4(4)  550(10) uM 1.8 270(3) 
37°C 18.9(3) uM 1.6 42.1(6)  640(20) uM 3.1 327(4) 
     
 
  
 
Glycocholic 
acid 
22°C 81(2) uM 2.5 20  4(1) mM 25.0 400(1) 
37°C 166(5) uM 3.0 20  5(1) mM 20.0 400(1) 
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APPENDIX C                                                                                                                         
SPECIFIC AIM 2 
C.1 Equation derivations 
A schematic of the shell balance used in deriving equations is provided in Figure C.1.  For 
dimensional consistency parameters are presented with SI units.  A conventional dialysis 
cartridge consists of several thousand semipermeable hollow fibers encased in a plastic shell.  
Blood flows through the inner lumens of the fibers, and sweep fluid (called dialysate) flows 
outside of the fibers countercurrent to the blood stream.  The “cleaned blood” that exits the 
dialyzer is then returned to the patient. 
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Figure C.1.  A typical dialyzer consists of two countercurrent flow paths with volumes of VB and VD with flow 
rates of QB and QD for blood and dialysate respectively.  The flow paths are segregated by a membrane of 
length l that can be separated into finite segments of size Δz.  The free solute concentrations ((CS)B and (CS)D 
for blood and dialysate respectively) change along the length, l, of the membrane as solute diffuses across the 
membrane at a rate proportional to the difference in concentrations on each side of the membrane and the 
membrane area/mass transport rate constant (kA) that is dependent on the solute and membrane that are 
being used.  Albumin-solute volumetric binding reactions occur at the rate RV that is dependent on the binder 
and solute involved. 
 
 As blood passes through the dialyzer, free binder (albumin), A, and free solute, S, in the 
blood (subscript B) associate to form the solute-binder complex, S●A, and the complex 
dissociates into free binder and solute: 
 
( ) ( ) ( )
a
d
k
B B B
k
S A A S• +         Equation C.1 
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where ka (m3 mol-1 s-1) and kd (s-1) are the reaction rate constants of association and dissociation, 
respectively, of the solute binder complex.  Molecules in the blood that are smaller than the 
molecular weight cutoff of the membrane being used will diffuse down their concentration 
gradient into the dialysate (subscript D).  Likewise, any molecule that has a higher concentration 
in the dialysate than in the blood stream will diffuse down its concentration gradient into the 
blood.   
 
( ) ( )B DS S           Equation C.2  
 
It is being assumed that the binder molecules are not able to cross the dialysis membrane.  Free 
binder present on the dialysate side will react with solute crossing the membrane.    
 
( ) ( ) ( )
a
d
k
D D D
k
A S S A+ •         Equation C.3 
 
For the one-to-one binding scheme presented here, the association equilibrium binding constant, 
KB (m3 mol-1), is defined as  
 
,
, ,
S A eqa
B
d S eq A eq
CkK
k C C
•= =         Equation C.4 
 
The concentrations of the complex, CS●A,eq, the solute, CS,eq, and the binder, CA,eq, are the 
concentrations at equilibrium (subscript eq).  The total solute and binder concentrations (whether 
the reactions are at equilibrium or not) are given by 
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,S total S SAC C C= +           Equation C.5 
,A total A SAC C C= +           Equation C.6 
 
A mass balance on the free solute on the blood side yields the ordinary differential equation 
 
( )
l
VRCC
l
kA
dz
CdQ BSBVBSDSBSB +−= )()(
)(
      Equation C.7 
 
where QB (m3 s-1) is the volumetric flow rate of the blood side, (CS)D (mol m-3) is the free solute 
concentration on the dialysate side, (CS)B (mol m-3) is the  concentration of free solute on the 
blood side, z (m) is the axial coordinate, k (m s-1) is the mass transfer coefficient, A (m2) is 
the membrane surface area for transport, l (m) is the axial length of the membrane, RSBV  (mol m
-
3 s-1) is the volumetric production rate of solute on the blood side, and VB (m3) is the volume of 
the blood side.  The equilibrium model described by Patzer was presented in terms of the total 
solute concentration as a function of axial position in the cartridge, but the kinetic model 
presented here is in terms of free solute concentration.  The volumetric production rate of free 
solute, RSV , is the sum of the production of free solute from the dissociation of the binder-solute 
complex and the loss of free solute resulting from the association of free solute with free binder 
 
,( )
S
V d SA a S A d SA a S A total SAR k C k C C k C k C C C= − = − −      Equation C.8 
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Here the superscript S on the volumetric production rate denotes that it is the production of 
solute.  The B in Equation C.7 denotes the blood side.  Substituting Equation C.8 into Equation 
C.7 yields 
 
( ) ( )( ) ( ) ( ) ( ) ( ) (( ) ( ) )tS B BB S D S B d SA B a S B A B SA Bd C VkAQ C C k C k C C Cdz l l= − + − −  
Equation C.9 
 
Similarly on the dialysate side 
 
( ) ( )( ) ( ) ( ) ( ) ( ) (( ) ( ) )tS D DD S B S D d SA D a S D A D SA Dd C VkAQ C C k C k C C Cdz l l− = − + − −  
Equation C.10 
 
Here the subscript D, denoting the dialysate side, replaces the subscript B used for the blood side.  
The negative on QD denotes the direction of flow as counter to the direction of increasing z.  
Countercurrent flow is the norm in dialysis. 
In the original paper describing BSD, to define these equations as functions of CS only, 
the fraction of albumin binding a solute molecule, Ψ (dimensionless), was introduced. 
 
SA
A SA
C
C C
Ψ=
+           
Equation C.11 
  
The fraction of binder associating with a solute molecule,Ψ, was also described as a function of 
the equilibrium binding constant, KB.  The equations can no longer be described in terms of CS 
only since it can no longer be assumed that the reactions are at equilibrium.  Two additional 
 111 
ODEs must be introduced to keep track of the amount of bound solute (CSA) on both the blood 
and dialysate sides.  It is assumed that no binder passes through the membrane. 
 
( ),( ) ( ) (( ) ( ) ) ( )SA B BB a S B A B total SA B d SA Bd C VQ k C C C k Cdz l= − −     
Equation C.12 
( ),( ) ( ) (( ) ( ) ) ( )SA D DD a S D A D total SA D d SA Dd C VQ k C C C k Cdz l− = − −    Equation C.13 
 
These equations can be normalized by introducing scaling relations 
 
zz
l
=
          
Equation C.14 
,
( )( )
[( ) ]
S B
S B
S B total in
CC
C
=
        
Equation C.15 
,
( )( )
[( ) ]
SA B
SA B
S B total in
CC
C
=
        
Equation C.16 
,
( )( )
[( ) ]
S D
S D
S B total in
CC
C
=
        
Equation C.17
 
 
,
( )( )
[( ) ]
SA D
SA D
S B total in
CC
C
=
       
Equation C.18 
 
When those substitutions are made we get 
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( )
( )
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, ,
, , , ,
([( ) ] ( ) )
[( ) ] ( ) [( ) ] ( )
( )
[( ) ] ( ) [( ) ] ( ) (( ) [( ) ] ( ) )
S B total in S B
S B total in S D S B total in S B
B
B
d S B total in SA B a S B total in S B A B total S B total in SA B
B
d C C kA C C C C
d zl Q l
V k C C k C C C C C
Q l
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+ − −

 

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Equation C.19
 
  
( )
( )
,
, ,
, , , ,
([( ) ] ( )
[( ) ] ( ) [( ) ] ( )
( )
[( ) ] ( ) [( ) ] ( ) (( ) [( ) ] ( ) )
S B total in S D
S B total in S B S B total in S D
D
D
d S B total in SA D a S B total in S D A D total S B total in SA D
D
d C C kA C C C C
d zl Q l
V k C C k C C C C C
Q l
= −
−
+ − −
−

 

  
 
Equation C.20 
 
( ), , , , ,([( ) ] ) ) [( ) ] ( ) (( ) [( ) ] ( ) ) [( ) ] ( )( )
S B total in SA B B
a S B total in S B A B total S B total in SA B d S B total in SA B
B
d C C V k C C C C C k C C
d zl Q l
= − −

  
  
 
Equation C.21 
 
( ), , , , ,([( ) ] ( ) ) [( ) ] ( ) (( ) [( ) ] ( ) ) [( ) ] ( )( )
S B total in SA D D
a S B total in S D A D total S B total in SA D d S B total in SA D
D
d C C V k C C C C C k C C
d zl Q l
= − −
−

  

 
Equation C.22 
 
Simplifying the equations 
 
( ) ( ), ,( ) ( ) ( ) ( ) ( ) (( ) [( ) ] ( ) )S B BS D S B d SA B a S B A B total S B total in SA B
B B
d C VkA C C k C k C C C C
dz Q Q
= − + − −

    

 
Equation C.23 
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( ) ( ), ,( ) ( ) ( ) ( ) ( ) (( ) [( ) ] ( ) )S D DS B S D d SA D a S D A D total S B total in SA D
D D
d C VkA C C k C k C C C C
dz Q Q
= − + − −
− −

    

  
Equation C.24 
 
( ), ,( ) ( ) (( ) [( ) ] ( ) ) ( )SA B B a S B A B total S B total in SA B d SA B
B
d C V k C C C C k C
dz Q
= − −

  

  
Equation C.25 
 
( ), ,( ) ( ) (( ) [( ) ] ( ) ) ( )SA D D a S D A D total S B total in SA D d SA D
D
d C V k C C C C k C
dz Q
= − −
−

  

  
Equation C.26 
 
The equations can be further simplified by introducing the following dimensionless groups 
  
BQ
kA
=κ           Equation C.27 
B
D
Q
Q
=α           Equation C.28 
B
dB
Q
kVDa =1           Equation C.29 
2
,[( ) ]
B a
B S B total in
V kDa
Q C
=
         
Equation C.30 
,
,
( )
[( ) ]
A B total
S B total in
C
C
ε =          Equation C.31 
B
D
V
V
=γ           Equation C.32 
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,
,
( )
( )
A D total
A B total
C
C
β =           Equation C.33 
 
Substitution of Equation C.27- Equation C.33 into the mass balance equations yields 
 
( ) 1 2( ) ( ) ( ) ( ) ( ) ( ( ) )S B S D S B SA B S B SA Bd C C C Da C Da C Cdz κ ε= − + − −

    

   Equation C.34 
2 1
( ) ( ) ( ( ) ) ( )SA B S B SA B SA B
d C Da C C Da C
dz
ε= − −

  

     Equation C.35 
( ) 1 2( ) ( ) ( ) ( ) ( ) ( ( ) ))S D S B S D SA D S D SA Dd C Da DaC C C C Cdz
γ γκ βε
α α α
= − + − −
− − −

    

  Equation C.36 
2 1( ) ( ) ( ( ) ) ( )SA D S D SA D SA D
d C Da DaC C C
dz
γ γ
βε
α α
= − −
− −

  

    Equation C.37 
 
with the initial conditions 
 
1~@0)~( == zC DS          
1~@0)~( == zC DAS  
0@])~[()~( == zCC inBSBS  
( ) [( ) ] @ 0SA B SA B inC C z= =          Equation C.38 
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C.2 Symbol definitions 
System 
parameters       
 
Units 
 
Meaning 
 
Definition 
       QB  L s
-1  Blood volumetric flow rate   
       QD  L s
-1  Dialysate volumetric flow rate   
       
(CS)B  mol L
-1  Concentration of unbound solute in the blood   
       
(CS)D  mol L
-1  
Concentration of unbound solute in the 
dialysate   
       
CSA  mol L
-1  Concentration of the albumin solute complex   
       CA  mol L
-1  Concentration of free albumin   
       CS  mol L
-1  Concentration of free solute   
       
CAt  mol L
-1  
Total concentration of albumin (the sum of 
the concentrations of free albumin and the 
albumin solute complex)   
       
(CAS)B  mol L
-1  
Concentration of the albumin solute complex 
on the blood side of the dialysis cartridge   
       
(CAS)D  mol L
-1  
Concentration of the albumin solute complex 
on the dialysate side of the dialysis cartridge   
       
(CA)Dt  mol L
-1  
Total concentration of albumin on the 
dialysate side of the dialysis membrane   
       
(CA)Bt  mol L
-1  
Total concentration of albumin on the blood 
side of the dialysis membrane   
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System 
parameters       
 
Units 
 
Meaning 
 
Definition 
[(CS)B]in  mol L
-1  
Concentration of unbound solute in the 
blood at the entrance to the dialysis 
cartridge   
[(CS)Bt]in  mol L
-1  
Total concentration of solute in the blood at 
the entrance to the dialysis cartridge 
(scaling factor for concentrations)   
       
(CS)Dt  mol L
-1  
Total concentration of solute in the 
dialysate   
       (CS)Bt  mol L
-1  Total concentration of solute in the blood    
       
[(CS)t]res  mol L
-1  
Total concentration of solute in the single 
compartment patient   
       
[(CA)t]res  mol L
-1  
Total albumin concentration in the single 
compartment patient   
       
[(CS)t]out  mol L
-1  
Total concentration of solute leaving the 
dialysis cartridge   
       z  m  Axial coordinate in the dialysate cartridge   
       
l  m  
Axial length of the dialysis cartridge 
(scaling factor for axial coordinate)   
       kA  L s
-1  Lumped surface area/mass transfer rate   
       
RVSB  mol s
-1 L-1  
Volumetric production rate of free solute on 
the blood side of the dialysis membrane   
       RVS  mol s
-1 L-1  Volumetric production rate of free solute   
       
kd  s
-1  
Rate of dissociation of the albumin solute 
complex (first order reaction)   
       
ka  L
  mol-1 s-1 Rate of association of the albumin solute complex (second order reaction)   
       KB  L mol
-1  Equilibrium binding constant  CAS  (CACS)
 -1 
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System 
parameters       
 
Units 
 
Meaning 
 
Definition 
VD  L  
Volume of the dialysate side of the dialysis 
cartridge   
       
VB  L  
Volume of the blood side of the dialysis 
cartridge   
       
Ψ    Fraction of albumin that has a solute molecule bound to it (at equilibrium) 
 CAS (CA + CAS)
 -1 
    KBCS (1+KB·CS)
 -1 
       
z
~
     Dimensionless axial coordinate  z  l
-1 
       
(CS
~
 )B     
Dimensionless free solute concentration on 
the blood side   (CS)B ([(CS)B
t]in) -1 
       
(CSA
~
 )B    
Dimensionless albumin/solute complex 
concentration on the blood side  (CAS)B ([(CS)B
t]in) -1 
       
(CS
~
 )D    
Dimensionless free solute concentration on 
the dialysate side   (CS)D ([(CS)B
t]in) -1 
       
(CSA
~
 )D     
Dimensionless albumin/solute complex 
concentration on the dialysate side  (CAS)D ([(CS)B
t]in) -1 
       
κ    Dimensionless mass transfer rate  kA QB
-1 
       
α    Dimensionless flow rate  QD QB
-1 
       
Da1    
Dimensionless reaction rate of dissociation of 
the albumin solute complex  VBkd  QB
-1 
       
Da2    
Dimensionless reaction rate of association of 
the albumin solute complex  Vbka (QB[(CS)B
t]in) -1 
       
ε    
Dimensionless total albumin (binder) 
concentration  (CA)B
t ([(CS)Bt]in) -1 
       
γ    
Ratio of volumes in the dialysate and blood 
sides of the dialysis cartridge  VD VB
-1 
       
β    
Ratio of the concentrations of albumin on the 
dialysate and blood sides  (CA)Dt  ((CA)Bt) -1 
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C.3 MATlab programs 
Subsection titles are the file names that were used for the programs.  All of the programs need to 
be in the same folder for MATlab to use them the way they are written. 
C.3.1 kinetic_BSD_model.m 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%% 
% 
%   Richard H. Miller 
%   University of Pittsburgh 
%   Department of Chemical and Petroleum Engineering 
% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%    
% 
%   kinetic_BSD_model.m 
%   This program solves the system of odes that were derived to describe  
%   the concentration profile in a dialysis cartridge used for BSD.  This 
%   is the system of equations derived for and presented in my  
%   dissertation. 
% 
%       REQUIRES THE FOLLOWING PROGRAMS IN THE SAME FOLDER AS THIS PROGRAM: 
%           poly_solv_kin_BSD.m 
%           bvp_bc_eq.m 
%           bvp_bc_kin.m 
%           bvp_init_eq.m 
%           bvp_init_kin.m 
%           equations_equilibrium_BSD.m 
%           equations_kinetic_BSD.m 
% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%% 
  
%Clear all variables/global variables/functions 
clear all 
clc 
disp('start') 
  
%DECLARE GLOBAL VARIABLES  
%so that I don't have to pass a ton of variables into functions 
    global C_alb_tot_bl 
    global C_alb_tot_dial 
    global C_solute_tot_in_bl 
    global Cs_free_bl 
    global Cas_bl 
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    global Cs_free_bl_DL 
    global Cas_bl_DL 
    global Ca_free_bl_DL 
    global KB 
    global alpha 
    global kappa 
    global gamma 
    global Da1 
    global Da2 
    global epsilon 
    global beta 
     
%DECLARE/DEFINE VARIABLES  
    C_alb_tot_bl  = 40/66000*1000 %moles/m^3 
    beta  = 0.1 
    KB  = .001 %m^3/mole 
    alpha  = 0.1 
    kappa  = 0.5 
    epsilon  = 1.1 
    Da1  = 0.1 
    Da2  = Da1*KB*epsilon*C_alb_tot_bl 
    gamma  =1; 
    C_alb_tot_dial  = beta*C_alb_tot_bl %moles/m^3 
    C_solute_tot_in_bl  = C_alb_tot_bl/epsilon 
    
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%% 
  
%DETERMINE INITIAL CONDITIONS 
    %Uses the function poly_solv_kin_BSD to create an array for the  
    %incoming concentrations on the blood side  
        conc = poly_solv_kin_BSD(C_solute_tot_in_bl, C_alb_tot_bl, KB);        
  
    %split up the solution into its indavidual concentrations 
        Cs_free_bl = conc(1); 
        Cas_bl = conc(2); 
        Ca_free_bl = conc(3); 
  
    %Convert to dimensionless concentrations.  Dimensionless quantities are 
    %denoted by _DL at the end of the variable name 
        Cs_free_bl_DL = Cs_free_bl/C_solute_tot_in_bl; 
        Cas_bl_DL = Cas_bl/C_solute_tot_in_bl; 
        Ca_free_bl_DL = Ca_free_bl/C_solute_tot_in_bl; 
        
%ODE SOLVERS 
    %INITIAL GUESS FOR BVP SOLVER 
    %create an array for initial guess values for the BVP solver 
    %(initial guess array returned by bvpinit) =  
    %bvpinit(define mesh points, @handle for function defining the guess  
    %at each point) 
        %kinetic BSD guess 
        solinit_kin = bvpinit(linspace(0,1,101),@bvp_init_kin); 
        %equilibrium BSD guess 
        solinit_eq  = bvpinit(linspace(0,1,101),@bvp_init_eq); 
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    %BVP SOLVERS 
    %Use the boundry value problem solver bvp4c to solve the equations 
    %defined in @equiations_functionname, with the boundary values 
    %defined by @bvp_bc_name, with the initial guess vector solinit_name 
        %kinetic BSD solution 
        sol_kin = bvp4c(@equations_kinetic_BSD,@bvp_bc_kin,solinit_kin); 
        %equilibrium solution (solves dimensional concentrations) 
        sol_eq  = bvp4c(@equations_equilibrium_BSD,@bvp_bc_eq,solinit_eq); 
     
    %Split the solution into concentrations for the free solute in the  
    %blood and the albumin solute complex to get the total concentration  
    %of solute 
        %kinetic BSD solution  
        Csfb_solution_kin = sol_kin.y(1,:); 
        Casb_solution_kin = sol_kin.y(2,:); 
        Cs_tot_sol_kin = Csfb_solution_kin + Casb_solution_kin; 
        Cs_tot_sol_kin_DL = Cs_tot_sol_kin./C_solute_tot_in_bl; 
         
        %equilibrium solution 
        Csfb_sol_eq  = sol_eq.y(1,:); 
        KBCs = KB.*Csfb_sol_eq; 
        Cs_tot_sol_eq = Csfb_sol_eq + C_alb_tot_bl.*(KBCs./(1+KBCs)); 
        %convert to dimensionless concentrations     
        Cs_tot_sol_eq_DL = Cs_tot_sol_eq./C_solute_tot_in_bl; 
  
%PLOT RESULTS         
    %clear figure 
    clf reset 
    %Hold the figure so that multiple plot commands can be made 
    hold on 
     
    plot(sol_kin.x,Cs_tot_sol_kin_DL,':','Color','k','LineWidth',1); 
    plot(sol_eq.x,Cs_tot_sol_eq_DL,'-','LineWidth',1) 
    legend('C~st kin','C~st eq');  
    ylabel('Cs~ total');xlabel('z~');xlim([0 1]);ylim([0 1.005]); 
  
    CS_TOTAL_KIN_COPY = Cs_tot_sol_kin_DL'; 
    POSSITION_KIN_COPY = sol_kin.x'; 
    CS_TOTAL_EQ_COPY = Cs_tot_sol_eq_DL'; 
    POSSITION_EQ_COPY = sol_eq.x'; 
    COPY_KIN = [POSSITION_KIN_COPY CS_TOTAL_KIN_COPY]; 
    COPY_EQ = [POSSITION_EQ_COPY CS_TOTAL_EQ_COPY]; 
     
disp('end'); 
  
 
 
 121 
C.3.2 poly_solv_kin_BSD.m 
function [concentration_array] = poly_solv_kin_BSD(Cst, Cat, Keq) 
%Determines the incoming concentrations to be used as the initial values 
%in the BVP solver.  Uses the total binder, total solute, and binding  
%constant to determine the concentrations of free solute, free binder,  
%and binder solute complex for the reaction:  
%binder + solute <---> binder solute complex 
  
%INPUTS: 
    %Cst = total incoming solute concentration 
    %Cat = total incoming binder concentration 
    %Keq = equilibrium binding constant of the reaction 
  
%DEFINE the objective function A*Cs^2 + B*Cs + C = 0 
    A = Keq; 
    B = 1 + (Keq*Cat) - (Keq*Cst); 
    C = -Cst; 
  
    obj_fun = @(x) (A*(x^2))+B*x + C; 
  
%DEFINE SEARCH RANGE for the root finding routine 
    search_range_low = 0; 
    search_range_high = Cst; 
    search_range = [search_range_low, search_range_high]; 
  
%DEFINE SOLVER TOLERENCE 
    x_tol = 0.00000001; 
  
%FIND ROOT OF OBJECTIVE FUNCTION 
    root_value = fzero(obj_fun, search_range, optimset('TolX', x_tol)); 
  
    Csf = root_value;  %Free solute concentration 
    Cas = Cst - Csf;  %binder solute complex concentration  
    Caf = Cat - Cas;  %free albumin concentration 
  
%RETURN ARRAY     
concentration_array = [Csf Cas Caf]; 
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C.3.3 bvp_bc_eq.m 
function res = bvp_bc_eq(ya,yb) 
global Cs_free_bl 
  
%Defines boundary conditions for the BVP solver in terms of the residuals 
%for the equilibrum BSD solver 
%formatted as [possition(array #)]-[value at possition] 
%ya: blood side at z_DL = 0 
%yb: dialysate at z_DL = 1 
  
res = [ ya(1)-Cs_free_bl 
        yb(2)]; 
C.3.4 bvp_bc_kin.m 
function res = bvp_bc_kin(ya,yb) 
  
global Cs_free_bl 
global Cas_bl 
  
%Defines boundary conditions for the BVP solver in terms of the residuals 
%for the kinetic BSD solver 
%formatted as [possition(array #)]-[value at possition] 
%ya: blood side at z_DL = 0 
%yb: dialysate at z_DL = 1 
  
res = [ ya(1)-Cs_free_bl 
        ya(2)-Cas_bl 
        yb(3) 
        yb(4)]; 
 
 
C.3.5 bvp_init_eq.m 
function guess_vector = bvp_init_eq(x) 
global Cs_free_bl 
 
%Defines an initial guess starting point for the boundary value problem %solver for the equilibrium BSD model 
  
guess_vector = [ -Cs_free_bl/2*x+Cs_free_bl   
                 -0.1*Cs_free_bl/2*x+0.1*Cs_free_bl];     
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C.3.6 bvp_init_kin.m 
function guess_vector = bvp_init_kin(x) 
  
global Cs_free_bl 
global Cas_bl 
 
%Defines an initial guess starting point for the boundary value problem %solver for the kinetic BSD model 
  
guess_vector = [ -Cs_free_bl/2*x+Cs_free_bl 
                 -Cas_bl/2*x+Cas_bl 
                 -0.1*Cs_free_bl/2*x+0.1*Cs_free_bl 
                 -0.1*Cas_bl/2*x+0.1*Cas_bl]; 
 
 
 
C.3.7 equations_equilibrium_BSD.m 
function [rhs_eq] = equations_equilibrium_BSD(ind_eq,dep_eq) 
%Defines the right hand side of the ODEs describing the equilibrium model  
%of BSD.   
 
global kappa 
global C_alb_tot_bl 
global KB 
global alpha 
global C_alb_tot_dial  
  
%Create some shortened local variable names for print formatting purposes 
CAB = C_alb_tot_bl; 
CAD = C_alb_tot_dial; 
kap = kappa; 
al = alpha; 
K = KB; 
ka=kap/al; 
  
rhs_eq = [1;2]; 
rhs_eq(1)=(kap)*(dep_eq(2)-dep_eq(1))*((1+CAB*(K/((1+K*dep_eq(1))^2)))^-1); 
rhs_eq(2)=(ka)*(dep_eq(2)-dep_eq(1))*((1+CAD*(K/((1+K*dep_eq(2))^2)))^-1); 
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C.3.8 equations_kinetic_BSD.m 
function [rhs_kin] = equations_kinetic_BSD(ind_vec_kin,dep_vec_kin) 
%Defines the right hand side of the ODEs describing the kinetic model of 
%BSD.   
  
global kappa 
global Da1 
global Da2 
global alpha 
global gamma 
global C_solute_tot_in_bl 
global C_alb_tot_bl 
global C_alb_tot_dial 
  
%shorten variable names for print formatting purposes 
a=dep_vec_kin(1);%Csb 
b=dep_vec_kin(2);%Csab 
c=dep_vec_kin(3);%Csd 
d=dep_vec_kin(4);%Csad 
CS = C_solute_tot_in_bl; 
CD = C_alb_tot_dial; 
ga = gamma/alpha; 
  
rhs_kin1=(kappa*(c-a))+(Da1*b)-((Da2/CS)*a*(C_alb_tot_bl-b)); 
rhs_kin2=((Da2/C_solute_tot_in_bl)*a*(C_alb_tot_bl-b))-(Da1*b); 
rhs_kin3=((-kappa/alpha)*(a-c))+((-ga)*Da1*d)-((-ga)*(Da2*CS)*c*(CD-d)); 
rhs_kin4=((-ga)*(Da2*CS)*c*(CD-d))-((-ga)*Da1*d); 
rhs_kin = [rhs_kin1; rhs_kin2; rhs_kin3; rhs_kin4]; 
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APPENDIX D                                                                                                                             
SPECIFIC AIM 3 
D.1 Slide dialyzer prototyping 
Dialysis fibers were excised from Exeltra cellulose triacetate (Baxter Healthcare Corporation, 
Deerfield, IL), Multiflow 60 AN69 (HOSPAL Industrie, Meyzieu, France), and Polyflux 11S 
polyarylethersulfone (Gambro Dialysatoren GmbH & Co. KG, Hechingen, Germany) 
commercial dialyzers.  A high speed rotary tool with a cutting wheel was used to remove the 
polycarbonate housing from the dialyzer.  The rotary tool was used at high speed in an attempt to 
melt the plastic housing as it was being cut to reduce the amount of saw dust getting into the 
fiber bed, and a vacuum was used to remove saw dust at the cut site as the cutting was performed 
(Figure 6.3).  Small bundles of ~50 fibers about 90-100 mm long were cut from the fiber bed 
with surgical scissors.  Polysulfone membranes kink easily, are very brittle, dry, and push away 
from each other due to static charge once the fiber bed is removed from the shell.  Cellulose 
triacetate fiber are quite thin (diameter), easily kinked, and easily broken.  AN69 membranes are 
on the larger side, and are somewhat robust to handling when compared to the other two 
membrane types used.  The AN69 and cellulose triacetate membranes are both packed wet with 
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glycerin.[73]  Attempts to use an albumin permeable cellulose triacetate bioreactor membrane 
were unsuccessful due to the fragility of the fibers during handling. 
Plastic shim stock (PETG, 0.03” thickness) (McMaster-Carr, Robbinsvile, NJ) was cut to 
fit on the microscope stage (80x100 mm) and a 15 mm hole was cut to accommodate the 
microscope objective. A 45x50 mm coverslip (1.5 thickness) was affixed over the hole using 
general purpose (thick, non-flowable) silicone sealant (RTV sealant, 732 Multi-Purpose Sealant, 
Dow Corning Corporation, Midland, MI) (Figure D.1).   
 
 
Figure D.1.  Plastic shim stock was cut to 80x100 mm.  A 15 mm hole was cut in the middle to accommodate a 
microscope objective.  A 45x50 mm cover slip was glued in place over the hole.  A bead of silicon was placed 
on either side of the hole to affix the dialysis fibers. 
 
A small bead of general purpose silicone sealant was laid about 1 mm from the edge on 
two opposing sides.  Ten fibers were evenly spaced across the cover slip, and the fibers were 
gently pressed into the silicone so that they were in contact with the cover slip.  A new bead of 
general purpose silicone sealant was laid to cover the outside 1 mm of the coverslip.  Two 
lengths of microbore tygon tubing (2” length, 0.040” ID, 0.070 OD) (Saint-Gobain, Granville, 
NY), were positions perpendicular to the fibers with the end of the tube just inside the silicone 
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bead to create a cross flow configuration through the extracapillary space of the slide.  A second 
1 mm bead of general purpose silicone sealant was laid around the outside of the coverslip on top 
of the first bead to sandwich the tubing.  A 50x50 mm (~0.03” thickness) borosilicate slide glass 
(Eastman Kodak Company, Rochester, NY) was placed on top and gently pressed to seat the 
coverslip and slide glass onto the tubing.  A small beaker was placed on top of the slide glass and 
the silicone was allowed to cure overnight (Figure D.2).   
 
 
Figure D.2.  The dialysis fibers were evenly spaced across the coverslip, and were gently pressed into the 
silicone.  Two pieces of tubing (2” length, 0.040” ID, 0.070 OD) were placed at the edge of the cover slip 
perpendicular to the dialysis fibers. 
 
The fibers were then wetted with general purpose silicone sealant, gently gathered together, and 
allowed to dry overnight.  This silicone coating served the purpose of sealing the membrane to 
prevent leaking and to gather the fibers to allow them to be inserted into a piece of tubing.  A 4 
cm piece of silicone tubing (0.125” ID, 0.188” OD) (Cole-Parmer, Vernon Hills, IL) was slid 
over the fibers on both sides of the slide dialyzer.  A bead of general purpose silicone sealant was 
laid around the outside of the slide that was just higher than the top of the slide glass and tubing 
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housing the fibers to create a dam that can be backfilled with silicone to encase and seal the 
fibers, the edge of the glass sandwich, and the bottom of the tubing housing the fibers.  The 
silicone was allowed to cure overnight.  The tubing housing the fibers was filled with flowable 
silicone sealant (RTV sealant, 734 Multi-Purpose Sealant, Dow Corning Corporation, Midland, 
MI) from the side toward the glass outward, and the dam around the edge of the slide was back 
filled with the flowable silicone from the edge of the glass outward.  A razor blade was used to 
cut back several millimeters up the tubing with the fibers, opening the fibers to flow but leaving 
a stub long enough to place a fitting over the tubing (Figure D.3). 
 
 
Figure D.3.  The fibers were bundled together and slid into a piece of tubing (0.125” ID, 0.188” OD).  Silicone 
sealant was used to fill the tubing, seal the area around the glass, and cover the fibers.  After the silicone had 
cured, the tubing housing the dialysis fibers was cut to expose the open fibers. 
 
The fittings I used were female-female luer lock connectors with one side bored out to the OD of 
the tubing used to house the fibers.  The fitting was placed just over the end of the tubing, and a 
bead of flowable RTV silicone sealant was put on the tubing at the front edge of the fitting.  The 
fitting was pushed the rest of the way onto the tubing, and additional silicone was allowed to 
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flow over the fitting to completely seal against leaks.  Barbed luer fitting were inserted into the 
tubing going into the extracapillary space (Figure D.4).  After an additional two days to allow all 
of the silicone to fully cure, the slides were connected to a syringe pump at a flow rate of 0.25 
ml/min to test for leaks. 
 
Figure D.4.  Female luer fittings were affixed to the tubing housing the fibers and entering the extracapillary 
space. 
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